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Recently, T cell based immunotherapies have moved to the forefront of cancer
immunotherapy with the success of Adoptive T cell therapy (ACT) and Immune checkpoint
blockade. ACT, where patients are treated with tumour infiltrating T cells (TILs), conferred
a clinical response rate of ~50%. Treatment with anti-CTLA4 and anti –PD1 therapy,
conferred response rates of up to 50%, greatly improving the overall survival of patients
with advanced melanoma amongst other cancer types. Despite the encouraging
outcomes, there are relatively low response rates coupled with the delay of weeks to
months before tumour shrinkage can be appreciated. Thus, understanding what tumour
intrinsic pathways contribute to non-responsiveness to immunotherapies and their effect
on T cells, to improve response rates, shorten time to treatment effect and developing
predictive biomarkers of response are vital to the care of cancer patients.
In order to identify possible tumour intrinsic pathways that could be perturbed to
improve responses to immunotherapy, a high-throughput in vitro screen with 850 different
bio-active compounds (Selleckchem), was designed to search for agents that could either
increase or decrease the resistance of melanoma tumour cells to T cell mediated killing.
Paired tumour samples and TILs from melanoma patients were used to assess which
compounds when used to treat the melanoma cell lines can enhance the cytotoxic activity
of the TILs against the paired melanoma sample, using a flow cytometry based assay in
which active caspase 3 was used as a read out of apoptosis. Heat shock protein 90
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(HSP90) inhibitors amongst compounds that improved T cell mediated cytotoxicity. We
show that treatment with the HSP90 inhibitor ganetespib (Synta) greatly improves T cell
mediated cytotoxicity of both human and murine cancer cells lines in vitro. Furthermore,
in vivo murine studies using the MC38/gp100 tumour model show that ganestespib in
combination with immune checkpoint blockade, resulted in superior antitumour effect and
survival compared to either treatment alone. Microarray analysis of human cell lines
treated with ganetespib in vitro revealed an increase in interferon alpha (IFN-α) response
genes including IFIT1, IFIT2 and IFIT3. Silencing IFIT genes abrogated the synergy
observed with ganetespib treatment and T cell mediated killing, suggesting that the IFN-α
response pathway plays an important role in this combination therapy. This work highlights
the importance of IFIT genes in response to T cell based immunotherapy and will enable
the emergence of a new combination therapy of HSP90 inhibitors and anti-CTLA4 for the
treatment of melanoma patients that will increase the percentage of patients responding
to immunotherapy and achieving long term responses.
To understand what factors influence CD8 T cell effector function at the tumour
site, we used a murine adoptive cellular therapy model in which B16, a gp100-expressing
tumour cell line was implanted in mice and treated with transgenic Pmel T cells, which
recognize gp100 in the context of H-2Db. Transferred Pmel T cells were recovered from
the spleen and tumour of the mice. To interrogate novel pathways which may inhibit the
functions of tumour-reactive T cells at the tumour site, microarray and genome-wide gene
expression analyses, were used to characterize the differential expression profiles among
Pmel T cells from different groups. 720 genes were differentially expressed by T cells
recovered from the tumour site, when compared with those recovered from the spleen.
Amongst them, was the transcription factors Runx2, a gene whose role has not been
described in T cells, to be one of the genes that were differentially expressed. In addition,
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we found that when Runx2 was absent in T cells they did a better job at controlling tumour
growth and vice versa. Further investigation revealed that Runx2 regulated processes in
T cells such as cytokine production and differentiation status, processes which are
important in controlling tumour growth. We are currently focused on understanding how
Runx2 controls these processes in an effort to provide ways to improve existing
immunotherapies or discover new ones.
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Chapter 1
Introduction and Background
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The human body is constantly bombarded by both external and internal ‘threats’ such as
pathogenic microbes, viruses and cancer. Whether the body succumbs to these threats is greatly
dependent on the integrity of the host immune system. Consisting of a cooperative network of
lymphoid organs, cells, humoral factors, and cytokines, the immune system can be divided into
two arms: innate and adaptive immunity that work hand-in-hand. Over the years, the important
role of the immune system in eradicating tumours has been well established. This concept of
immunosurveilance was first proposed by Ehrlich in 1909. He posited that the immune system
constantly recognized and eliminated evolving tumours before clinical manifestations could
occur(1). Burnet later polished this notion with the proposal that genetic mutations occurring in
somatic cells lead to the development of tumours and the immune system was vital in eradicating
these mutant cells(2). This phenomenon would later be confirmed by studies from several groups,
primarily through the observation that mice and humans with innate and adaptive immunedeficiencies were more likely to develop tumours (3, 4). Amongst the adaptive immune cells, T
lymphocytes particularly CD8 T cells, are vital in tumour elimination as first shown in adoptive
transfer experiments in murine tumour models (5-7). These studies were translated to humans
with the treatment of melanoma and renal carcinoma with tumour-infiltrating lymphocytes
(TILs)(8), paving the way for the development of numerous immunotherapy options for cancer
patients. While there have been great strides in the development of immunotherapies, there is
room for improvement as many cancer patients do not benefit from immunotherapy. Therefore, in
this study considerable efforts were made, using preclinical models, to identify potential pathways
or molecules in tumours and T cells that could be perturbed to improve responses to T cell based
immunotherapy. It is hoped that this knowledge will inform rationale combination therapies that
can provide longer lasting patient outcomes in cancer patients treated with immunotherapy. I will
first introduce the general concept of the generation of an immune response and the signals that
lead to optimal T cell activation. In addition, I will introduce the concept of T cell mediated
antitumour immunity and how it can be suppressed. I will also summarize current strategies of T
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cell mediated immunotherapy. Finally, I will focus on the known and emerging underlying
mechanisms through tumours cells be unresponsive to T cell mediated immunotherapy.

Generation of a CD8 T cell mediated immune response
Although an effective CD8 T cell antitumour immune response has unique attributes, a great deal
of our current knowledge on the generation of a CD8 T cell response has come from the study of
acute viral infections. Following an encounter with antigen, naïve CD8 T cells follow a classical
three phase response(9). Phase 1 begins with initial activation characterized by simultaneous
clonal expansion of antigen specific cells and procurement of peripheral tissue homing
capabilities, effector cytokine release, and cytotoxic activity. Phase 2 involves prompt, apoptosis
induced contraction of antigen specific effector T cells. Finally, phase 3 involves the development
of a persistent population of antigen experienced cells known as memory T cells. A comparable
response has also been observed in vivo when tumour specific T cells are stimulated with a
vaccine, accompanied by adjuvants and immunopotentiators(10). Important attributes that
distinguish the memory CD8 T cells in phase 3 include increased precursor frequency compared
to naïve cells, antigen independent self-renewal via homeostatic proliferation sustained by the
cytokines interleukin 7 (IL7) and IL15, in addition to the rapid acquisition of effector functions and
clonal proliferation following antigen re-stimulation (11-13). These characteristics are jointly
known as the hallmarks of immunologic memory providing the host with long-lived protection from
future pathogenic encounters. CD4 T helper cells (Th) are vital in the development and
maintenance antigen specific memory CD8 T cells. As such, the ability of memory CD8 T cells to
function, persist and effectively control a secondary challenge is impaired in the absence of Th
(14, 15). Although tumour reactive precursor CD8 T cells are present in cancer patients, they fail
to control and eliminate tumours. Studies over the years have shown these cells to be anergic or
exhausted as a result of several immunosuppressive factors present within the host. An
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understanding of these factors have informed the development of several T cell based
immunotherapies for the treatment of cancer.

The initiation of T cell responses
Immune cells function in a precisely controlled sequential manner to provide protective immune
responses. As such T cell activation is a tightly regulated process. The interaction between T cells
and antigen presenting cells (APCs), including dendritic cells (DCs), B cells and macrophages, is
central to the initiation of a T cell response. This interaction provides a platform for signal
exchange between the two cell types. Adequate T cell activation requires the integration of
antigen-dependent signals, costimulatory signals and appropriate cytokine stimulation. The
mechanism of T cell activation was previously described as a two-signal model involving only
antigen-dependent signals and antigen-independent costimulatory signals. With the discovery
that cytokines are essential for optimal activation, differentiation, function and generation of
memory this model has now been revised and is now known as a three-signal model (Figure 1).
Establishment of the two-signal model
Brescher and Cohn, are credited with the concept of the two-signal model for T cell activation as
they attempted to explain self-tolerance in the periphery(16). They postulated that activation of
thymic precursor cells requires the integration of antigen-mediated interactions with other nonantigen specific pathways and that interaction of antigen alone with precursor cells could lead to
anergy. Their original paper lacked supporting data but overs the years, their model has been
confirmed and refined by many experimental observations. The first report supporting the twosignal model came from Lafferty et al. They compared allogenic reactions between different
strains of the same species and strains from different species and found that allogeneic reactions
are much higher between different strains within a species compared strains from different
species(17). To explain these unexpected result, they proposed a model of cell interaction which
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incorporated Brescher’s second signal model, suggesting that this second signal was a speciesspecific costimulatory signal. While TCR/MHC interactions comprise the first signal in the twosignal model(18), the second signal was first shown to be provided by surface molecules on
APCs(19, 20). Investigators observed that even though the antigenic signal was intact in T cells
as evidenced by increased intracellular Ca2+ flux, both murine and human T cell clones were not
activated by peptide-pulsed, metabolically inactive APCs or purified MHC molecules on artificial
membranes. These observations suggested that the lack of activation of murine and human T cell
clones under these conditions was caused by other defects of the APCs. In the early 90’s,
Janeway and Matzinger provided additional theories concerning the expression of inducible
accessory molecules on APCs. Janeway pointed out that quiescent APCs lack the ability to
provide help for T cell activation following the observation that full T cell activation required the
complete Freund’s adjuvant (CFA) for peptide or protein challenges. He concluded that, to induce
an immune response, quiescent APCs must be activated by microbial products similar to those in
CFA(21). Toll-like receptors (TLRs) were soon identified confirming and expanding upon
Janeway’s theory. Interaction of TLRs on APCs with pathogen-associated molecular patterns
(PAMPs) derived from microbial products, leads to the surface upregulation of accessory
molecules on APCs, now known as costimulatory molecules. These molecules provide the
second signal of the two-signal model for T cell activation. This theory, however, only partially
explained T cell activation in infectious diseases. It failed to explain other common immune
responses, such as immune responses related to transplantation and tumours, and autoimmune
responses. Matzinger then posited the danger signal model where, danger signals released by
injured cells activated quiescent APCs, subsequently increasing the expression of costimulatory
molecules(22). Many types of danger signals have since then been identified including
mammalian DNA, RNA and heat-shock proteins, as well as PAMPs on bacteria(23).
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Signal one: Antigen-dependent signal
The recognition of the peptide-MHC (pMHC), present on the surface of APCs, by the T
cell receptor (TCR) provides the initial signal and is required for T cell activation indicating that T
cells are stimulated in an antigen-specific manner. Expressed on the cell surface of T cells, TCRs
consist of two transmembrane units, TCR- and TCR-. These units are rearranged during the
process of T cell development in the thymus. A cluster of genes on chromosome 6 in humans and
17 in mice, encode for MHC molecules expressed by APCs. MHC class I and MHC class II are
two major forms of these polymorphic membrane-bound glycoproteins interacting with receptors
on CD8 T cells and CD4 T cells, respectively. As such, mature T cells can be classified into CD4
T helper (Th) cells and CD8 T cells (CTLs) based on the expression of these two receptors. The
binding of pMHC complexes to TCRs delivers activation signals transmitted into the T cell
cytoplasm via the CD3 complex (24). Following TCR engagement, tyrosine residues located in
immunoreceptor-based tyrosine activation motifs (ITAMs) on the CD3 complex are
phosphorylated by Lck/Fyn, belonging to the Src family of protein tyrosine kinases. ZAP70 then
binds to the phosphorylated CD3 complex via its SH2 domain, and gets activated by
autophosphorylation. ZAP-70 then propels TCR activation via phosphorylation several molecules
including Vav, PLC and SLP-76 leading to the initiation of downstream signaling cascades.
Finally, TCR engagement induces the activation of several pathways controlling T cell effector
functions, such as the NFAT and NF-B pathways (25).
Signal two: Co-stimulation
The second signal required for optimal T cell activation is co-stimulation. The prototypic molecule
that delivers the second signal for T cell activation is the co-stimulatory receptor CD28, a member
of the immunoglobulin (Ig) superfamily of receptors. CD28 is constitutively expressed on both
naïve and activated T cells(26). Following TCR ligation, CD28 on the T cells interacts with
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CD80/CD86 on APCs. This interaction induces the phosphorylation of tyrosine residues on CD28,
recruiting the SH-2 domain containing kinases, PI3K and Grb2. CD28 signaling amplifies the
magnitude and duration of T cell responses, leading to T cell proliferation, differentiation and
upregulation of survival genes such as BCL-2 and Bcl-XL(27). This signal is critical as lack thereof
can lead to T cell anergy. Another member of the Ig superfamily which enhances T cell responses
is, Inducible co-stimulator (ICOS). Mice with defects in ICOS and its ligand, ICOSL, signaling
have severely impaired primary T cell responses, especially Th2 responses(28). Additional
costimulatory molecules include CD27/CD70, OX40/OX40L, 4-1BB/4-1BBL, HVEM/LIGHT and
CD40/CD40L, belonging to the tumour necrosis factor (TNF) / TNF receptor (TNFR)
superfamily(29). In general, members of the TNF/TNFR family stimulate T cell proliferation and
cytokine production following initial T cell activation.
Following T cell activation is the upregulation of inhibitory receptors such as CTLA-4 which
dampen T cell activation to prevent autoimmunity once the ‘threat’ is cleared. Additional coinhibitory receptors include PD1, LAG3, TIM3 and BTLA(30). Ultimately, the fate of T cell
activation is determined by the integration of multiple co-receptors in T cell-APC focal synapses.
In the context of co-stimulatory receptors such as OX40, 4-1BB and ICOS, the outcome is a
favourable sustained T cell response characterized by increased proliferation, differentiation,
cytokine production, survival and memory. Whereas co-inhibitory receptors such as CTLA-4, PD1
and LAG-3 could result in the opposite effect, in addition to T cell anergy and exhaustion. In
summary, all of these discoveries shed light on the fact that T cell activation is more complex than
previously thought. T cell activation is the result of the binding of the TCR with pMHC complex,
and interactions of a variety of costimulatory molecules expressed on T cells and APCs. In
addition to the nature of TCR stimulation, the efficiency of T cell activation is controlled by a large
network comprised of a variety of costimulatory molecules (Figure 2).
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Signal three: Cytokine stimulation
While the two-signal model was the central concept and foundation for T cell activation, it is now
known that appropriate cytokine stimulation is also required for optimal T cell activation.
Mescher and Curtsinger first demonstrated this concept using in vitro studies(31, 32). Beads
conjugated with pMHC complexes and costimulatory molecules (artificial APCs) were used to
stimulate purified CD8 T cells and results indicated that signal 1 and 2 were sufficient to induce
T cell proliferation and IL2 production but not cytotoxic activity. Addition of the cytokine IL12
provided the third signal for cytotoxic activity of the CD8 T cells. Similarly, their in vivo studies
also confirmed this finding as the presence of only signal 1 and 2 and absence of IL12 resulted
in peripheral tolerance of CD8 T cells(33). This phenomenon was also observed in other
models. Studies from Filatenkov and colleagues evaluating the coordinated efforts between
CD4 and CD8 T cells in the development of an effective cytotoxic T lymphocyte (CTL) response,
showed that Th cells conditioned dendritic cells to produce IL-12 and that IL-12 was necessary
to sup-port development of CD8 T cell effector functions and graft rejection(34). Type I
interferons (IFN-α and IFN-β) and IL21 were subsequently identified as additional cytokines that
can also provide signal 3. Unlike IL12 and IFN-α/β, IL21 stimulation results in the development
of cytotoxic activity but not IFN- upon re-stimulation. The gene expression pattern of cells
stimulated with IL12 and IFN-α/β along with signal 1 and 2 was evaluated by Agarwal and
colleagues(35). When naïve cells were stimulated for 3 days with artificial APCs, transient gene
expression changes were observed which reverted to naive levels by 72 hours. However, in the
presence of either IL12 or IFN-α/β, the changes in gene expression increased and persisted at
72 hours, as well as additional changes consistent with the induction of a critical sustained
differentiation program in CD8 T cell function and memory. Many of the genes regulated by IL12
and IFN-α/β such as granzymes, IFN- CD25, OX40, and Bcl-3, are involved in effector
functions, proliferation and co-stimulation, survival, trafficking, and migration of T cells.
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Therefore signal 3 provided by the cytokines IL12 and IFN-α/β play a critical role in
transplantation, tumour biology and vaccine development as well as other T cell mediated
immune responses.
T cell mediated antitumour response
As mentioned above, adoptive transfer experiments in murine models informed the process of
elimination of cancer cells by T cells. Particularly the CD8 T cell subtype capable of cytotoxic
activity. The positive clinical outcomes of cancer patients, which received in vitro expanded
tumour-reactive T cells, provided powerful proof that CD8 T cells can mediate objective cancer
regression (36). As such, much more effort has been dedicated to their role in tumour
immunosurveillance compared to CD4 T cells. Moreover, the major histocompatibility molecule
(MHC) class I, indispensable for CD8 T cell activation, is expressed by most cells, including some
cancer cells. Activated CD8 T cells can therefore, recognize and lyse tumour cells. Activated CD8
T cells or cytotoxic T lymphocytes (CTLs) kill tumour cells via two major mechanisms: secretion
of cytotoxic granules and the Fas/FasL death pathway (37). Granzymes and perforin, which are
pre-synthesize cytotoxic proteins stored in lysosomes, are released upon CD8 T cell activation to
lyse the tumour cells. The release of these cytotoxic proteins is targeted to tumour cells in a
specific manner such that they are not released into the extracellular milieu. They cleave critical
substrates, which initiate apoptosis or DNA fragmentation in tumour cells. The importance of
granzymes and perforin in antitumour immunity was demonstrated using deficient mice.
Compared to wild-type mice, perforin deficient mice are more susceptible to methylcholanthrene
induced tumours, while granzyme A and granzyme B deficient CTLs were unable to induce DNA
framentation(38). Furthermore, blocking the granzyme B/perforin pathway via overexpression of
the serine protease inhibitor PI-6, is associated with resistance to CTL-mediated tumour
clearance (39, 40). In an independent study, the ligation of Fas ligand (FasL), expressed on the
surface of CTLs, with the Fas receptor on tumour cells triggered apoptosis through the classical
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caspase pathway (37). In addition to contact dependent cytotoxic mechanisms through cytotoxic
granules and Fas/FasL interactions, CTLs can also kill tumour cells through contact independent
mechanisms. This is achieved through release of several cytokines including interferon gamma
(IFN-) and tumour necrosis factor alpha (TNF-). TNF- binds to receptors expressed by tumour
cells inducing activation of the caspase pathway, leading to tumour cell apoptosis. IFN- interacts
with specific receptors, ubiquitously expressed on all nucleated cells. This interaction initiates the
JAK-STAT pathway, activating the expression of several genes including MHC molecules, the
antigen processing and presentation machinery, as well as increasing antigen presentation(41).
In addition, IFN-, through Fas/FasL upregulation, can induce apoptosis in tumour cell via
caspase-1. IFN-, together with TNF-alpha trigger the production of reactive oxygen species
(ROS) and NO, which might also inhibit the tumour growth (42). Chemokines produced by CTLs,
such as RANTES, also contribute to the recruitment and activation of innate immune effector cells
to control tumour growth (43).
Suppression of the T cell mediated antitumour immune response
The cancer immunity cycle is series of sequential steps involved in the generation of an effective
anti-tumour immune response (44, 45). Beginning at the tumour site, APCs capture and process
antigens released by oncogenesis. These antigens vary in type ranging from differentiation
antigens, overexpressed antigens to mutational neoantigens(46-48). Following migration to the
lymph nodes, APCs present the processed antigens to T cells in the context of MHC, thereby
priming and activating effector T cell responses. T cell priming has conventionally been thought
to occur exclusively in tumour-draining lymph nodes. However, spontaneously organized tertiary
lymphoid organ structures can be also found within tumours signifying that T cell education may
occur within the tumour bed(49). Activated T cells migrate to the tumour bed where the TCR
recognizes its cognate peptide in the context of MHC. Recognition of tumour cells leads to their
T cell mediated lysis. This further releases additional TAAs thereby propagating the cycle.
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Interruption of the cycle at any step can impede the generation an antitumour immune response.
Over the years, many tumour related factors, that impede the generation antitumour responses,
have been identified(45). Given that TILs are such significant prognostic markers for tumour
progression across multiple tumour types, understanding the processes involved in their
suppression is essential to the improvement of current therapeutic strategies and development of
novel therapeutic strategies. In this section, I will outline direct and indirect ways in which tumours
suppress several steps in the generation of an effective antitumour immune response; these
range from generation of tumour-reactive T cells to their homing, recognition and killing of tumour
cells.
Suppression of T cell priming
As reviewed above the first two steps of the cancer immunity cycle involve APCs which
process and present tumour antigens to T cells, as well as provide essential co-stimulatory
signals. As such, APCs are particularly important for the coordination of an anti-tumour immune
response. As professional APCs, DCs are the major type cell type that present TAAs to both B
cells and T cells, generating an antigen-specific antitumour response. Optimal priming of tumourreactive T cells depends on the apt differentiation and maturation of DCs, which provide effective
antigen stimulation and co-stimulation. The tumour microenvironment can however be
suppressive to the differentiation and maturation of DCs(50, 51). In mice and humans, defective
dendritic cell function is often associated with deregulation of DC maturation. Mature DCs are
located in peripheral lymphoid organs such as the spleen and lymph nodes. They express robust
levels of MHC and costimulatory molecules and activate tumour-reactive T cells to initiate a T cell
mediated antitumour immune responses. In contrast, immature/partially differentiated DCs are
located in the periphery, express intermediate amounts of MHC molecules, low levels of
costimulatory molecules as well as high levels of immunosuppressive cytokines and inhibitory
molecules. They inefficiently process and present TAAs to T cells inducing the loss of function of
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tumour-reactive T cells (52). All-in-all immature DCs mediate immune tolerance to tumours,
inducing anergy of effector T cells and/or favouring the expansion of T regulatory cells (Tregs) in
the lymph nodes or at tumour sites (53, 54). Till date several tumour secreted factors which
suppress DC maturation have been identified. Vascular endothelial growth factor (VEGF)
produced by tumour cells was one of the first factors reported to induce immature/partially
differentiated DCs (51). In addition to suppression of DC maturation, VEGF can also induce high
levels of PDL1 expression thereby also impairing DC function(55). Additional tumour derived
factors that disrupt DC maturation and function include macrophage colony stimulating factor (MCSF), Interleukin 6 (IL6), IL10, transforming growth factor beta (TGF-β) which inhibit
differentiation of DC (56-58), as well as physiological stimuli such as hypoxia and lactic acid(5961). Finally, immature DCs fail to secrete appropriate chemokines important in recruiting effector
cells to the tumour(62). In summary, normal DC differentiation, maturation and function are
essential components of T cell priming and disruption of this process via tumour-mediated
immune suppression leads to tumour immune tolerance. Current strategies aimed at relieving this
immune

suppression

include

blocking

these

aforementioned

tumour

secreted

immunosuppressive molecules, stimulating DC maturation via administration of TLR agonists or
CD40 agonistic antibodies, as well as generating potent DC-vaccines ex vivo.
Suppression of T cell homing
Chemokines play a critical role in T cell trafficking or homing to the tumour. As such, tumours
disrupt normal chemokine expression, greatly contributing to impaired T cell trafficking. Tumours
with a great number of TILs express high levels of established T-cell-attracting chemokines,
including chemokine (C-C motif) ligand 2 (CCL2), CCL3, CCL4, CCL5, chemokine (C-X-C motif)
ligand 9 (CXCL9), and CXCL10(63). In the tumour milieu, these chemokines can also be induced
by IFN- secreted by T cells. From observations in murine models, it is thought that a few T cells
initially infiltrate tumours along a chemokine gradient, followed by a large influx of both specific
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and nonspecific T cells as a result of a positive feedback loop that amplifies these T cell attracting
chemokines(64, 65). In tumour cells, it is well known that aberrant post-translational modifications
occurs in expressed chemokines. Changes in their cleavage, deamination and glycosylation
results in dramatically altered activities of expressed chemokines (66, 67). For instance, reactive
oxygen species (ROS) can induce nitrosylation of CCL2, an important chemokine for the
recruitment of CTLs to the tumour site(68). This post translational modification abrogates the
ability of CCL2 to attract tumour-specific CTLs, instead attracting myeloid-derived suppressor
cells (MDSCs) to the tumour bed(69). Additionally proteolytic processing of CXCL11, an important
chemokine that recruits CXCR3 expressing effector T cells, could be significantly altered. This
weakens CXCL11 binding and signaling, greatly decreasing lymphocyte homing (63, 64, 67).
Furthermore, CCL22 expression in ovarian and breast cancer can result in recruitment of Tregs
within tumours forming an immunosuppressive microenvironment (70). Hence, the deregulation
of chemokine expression is an important tumour immune escape mechanism.
Suppression of T cell extravasation
In addition to the chemokine gradient, the vascular endothelium also plays an important role in T
cell trafficking, particularly transmigration of T cells through the vascular endothelium into target
tissue in a process known as extravasation. T cell extravasation through the endothelium into the
tumour is a multi-step process that includes rolling and adhesion to endothelial cells and
subsequent diapedesis. The tumour endothelium can, however, be prohibitive in nature to T cell
transmigration, depending on the type and quantity of adhesion molecules expressed (36, 71,
72). Key adhesion molecules important for extravasation include intercellular adhesion molecule1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1), expressed on the endothelium.
ICAM-1 and VCAM-1 are known to be upregulated by soluble factors such tumour necrosis factoralpha (TNF-α) often expressed within the tumour microenvironment, albeit in low amounts by
tumour cells themselves(73). TNF-α is a known activator of endothelial cells and T cell adhesion.
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However, in the presence of angiogenic promoting factors such as basic fibroblast growth factor
(bFGF) or VEGF, TNF-α stimulation is unable to induce expression of ICAM-1 and VCAM-1 on
endothelial cells(74, 75). In addition to VEGF, the presence of endothelins and their receptors
within the tumour microenvironment is detrimental to the expression of adhesion molecules.
Frequently upregulated in a number of cancers including ovarian, colon, breast, prostate and renal
cancer endothelin (ET) peptide ligands ET-1, -2, -3, and -4 are potent regulators of endothelial
cell biology(76-78). They are involved in autocrine and paracrine loops that promote
angiogenesis, proliferation, protection from apoptosis, vasculogenesis, invasion and metastatic
dissemination of tumours. Through interactions with VEGF, endothelins regulate several aspects
of angiogenesis, including endothelial cell proliferation, migration, invasion, vessel formation, and
neovascularization. The suppressive effects of VEGF and endothelin can be commonly induced
by the highly reactive free radical nitric oxide (NO)(74, 79). NO decreases T cell-endothelial
interactions via downregulating the expression of the important adhesion molecules Pselectin,
ICAM-1, and VCAM-1. As such, inhibition of the NO-producing enzyme, nitric oxide synthase
(NOS), enhances both the rolling and adhesion of CD8 T cells on tumour vasculature.
Independent of adhesive mechanisms, the tumour vasculature can also influence the nature of T
cell infiltration in tumours. Endothelial cells can, for example, express a number of molecules such
as FasL and TNF-related apoptosis-inducing ligand (TRAIL) which can interact with
corresponding receptors on effector CD8 T cells leading to their suppression and death(80, 81).
Furthermore, immunosuppressive molecules such as TIM-3, IL-10, TGFb, PDL1, PDL2, B7-H3
and PGE2 can also be expressed by the tumour endothelium(76, 82-88). Therefore, the role of
tumour endothelial cells is mostly immunosuppressive and is maintained by tumour cells through
paracrine mechanisms.
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Suppression of T cell interaction and recognition of tumour cells
Once CD8 T cells emerge into the tumour bed, they can encounter additional immuosuppresive
cell populations within the tumour microenvironment. T regulatory cells (Tregs) are one of such
cell types encountered(89-91). They can be actively recruited and local expanded to effectively
suppress T cell effector functions. As such, infiltration of Tregs is frequently associated with a
poor prognosis, although their presence may also be indicative of an ongoing immune response.
Characterized by the markers, CD4+ CD25+ FoxP3+, Treg cells can be divided into natural Tregs
(nTregs) and inducible Tregs (iTregs)(92). nTregs are thymically derived and maintained
peripherally by TGF-β, while iTreg are induced from naive CD4+ T cell precursors periphery. A
number of studies indicate that Treg cells accumulate within tumours in a clonally restricted
manner and are specific for tumour antigens. Treg cells are therefore, activated in an antigenspecific manner and can suppress T cell function through both specific and nonspecific
mechanisms(91, 93). Tregs cells can be actively recruited by chemokines such as CCL22
secreted by tumour cells tumours and tumour associated macrophages(70). In addition to
recruiting nTregs, the tumour microenvironment favours the continued expansion of nTregs as
well as the generation of iTreg cells via IL-10, TGF-β and adenosine derived from either tumourresident immunosuppressive DCs and Tie-2+ monocytes (TEMs) or tumour cells(94). Cytokines
such as TGF-β, IL-10, and IL- 35, secrete by Tregs suppress effector T cell expansion and effector
cytokine secretion. Another mechanism through which Tregs suppress effector cells is through
competitive consumption of IL2 in the tumour microenvironment, thus limiting effector T cell
expansion and function(95). Tregs express high levels of the IL-2 receptor alpha (IL-2Rα, also
known as CD25) and hence have higher affinity for IL2. While IL2 signaling on Treg cells is not
required for their suppressive function, IL2 is required to maintain their metabolic homeostasis
and competitive fitness in vivo. Thus, Treg cells depend on paracrine support from T effector cells,
which secrete IL-2, for expanding and maintaining local tolerance. In addition, Tregs can directly
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kill T cells via TRAIL or granzyme B mediated cytotoxicity (96, 97). Finally, Tregs can crosstalk
with DCs, inducing the expression of TGF-β, IDO and IL-10 expression from DCs through direct
interactions(91).
While a number of suppressive myeloid lineage cells have been identified within tumours,
myeloid derived suppressor cells (MDSCs) are the best described. Often found in great numbers
within tumour and in circulation of cancer patients, they are potent inhibitors of effector T cell
functions(98). Recruited from the bone marrow, MDSCs are expanded in the peripheral blood
through interactions with BV8 and endocrine-gland-derived VEGF (EGVEGF)(99). Once in
circulation, MDSCs can be recruited a number of chemokines, including CCL2, CXCL5, CXCL12,
and stem cell factor (SCF) to the tumour site(100). Within the tumour, MDSCs suppress T cells
through the production of IL10, TFG-β, arginase I, as well as reactive oxygen species (ROS).
Furthermore, MDSCs can also expand Treg cells within the tumour microenvironment (59, 86).
Nevertheless, studies have shown that MDSCs can be phenotypically plastic. They can acquire
the features of tumour-rejecting monocytes and even APCs if the right conditions are met. For
instance, the cytokines IFN- and IL12 have been shown to convert MDSCs into APC-like cells
that activate and enhance the functions of T cells in vitro and in vivo (101, 102). Therapies that
deplete MDSCs or change their phenotype to a more favourable one are attractive for cancer
treatment.
Suppression of T cell mediated killing of tumour cells
Finally, once T cells successfully make their way through the barriers of the tumour vasculature
and stroma, they can face additional immunosuppressive factors that interfere with effective
recognition and/or killing of tumour cells. As previously described, T cells rely greatly on pMHCTCR interactions in order to recognize targets and perform their effector functions. It is well
established that that tumours express protein products or peptides that can be recognized by the
immune system as "non-self". This peptides are derived from a range of proteins including
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overexpressed self-proteins (including cancer testis and other immune-privileged site antigens)
to novel mutational epitopes resulting from nonsynonymous somatic mutations (47, 103). T cells
recognizing these tumour associated peptides have been identified in melanoma as well as other
cancer types. Tumours have however developed mechanisms to avoid T cell recognition by T
cells through loss of immunogenic peptides from the tumour surface. This could be accompanied
by loss of expression or downregulation of the antigen processing and presentation machinery,
as well as downregulation or complete loss of MHC I expression(104). Selective pressure from
mutation, genetic loss, or epigenetic silencing could be responsible for this observation. In
addition, tumour intrinsic oncogenic signaling could also contribute to this effect as inhibition of
certain pathways can increase MHC I and surface antigens on tumour cells (104, 105). This
aberration in antigen processing and presentation is associated with poor prognosis of disease
and poor clinical outcomes.
Tumours can also express surface molecules including the TNF family members FasL
and TRAIL that can directly kill T cells following interaction with the receptors on T cells(106).
They can also express the ligands to co-inhibitory receptors on T cells, such as PDL1, PDL2 and
B7-H4 which can suppress T cell functions arresting tumour rejection (107, 108). Furthermore,
the microenvironment in close proximity to tumour cells can be quite toxic for optimal CTL function.
Soluble mediators, such as IL-10, PGE2, TGF-β, histamine, hydrogen peroxide, and adenosine,
secreted by tumour cells, can directly inhibit CTLs(106). Moreover, metabolic substrate
deprivation as a result of competitive consumption by tumour cells and/or active depletion by
enzymes such as IDO and arginase can further diminish T cell effector function(109). Finally, the
hypoxic conditions and the relatively lower extracellular pH reminiscent of the tumour interstitium
can negatively affect CTL function(90).

30

T cell mediated cancer immunotherapy
Given the crucial role of tumour-reactive T cells in antitumour immune responses and an
increased understanding of tumour suppressive mechanisms, T cell mediated cancer
immunotherapy has been exploited for several decades to harness or boost the immune system
to eliminate tumours. Till date many immunotherapies have been developed and successfully
implemented for the treatment of various cancer types including melanoma, renal cell carcinoma,
non-small cell lung cancer and lymphoma. Cancer immunotherapy can be divided into four major
categories: cancer vaccines, cytokine based therapy, adoptive cellular therapy and immune
checkpoint therapy.
Cancer vaccines
The concept of cancer vaccines was borrowed from the successful development of vaccines
against infectious diseases. Cancer vaccines illicit recognition and destruction of tumour cells by
activating the immune system. Common forms of cancer vaccines being investigated for cancer
treatment include protein vaccines, whole cell vaccines, DNA vaccines, peptide vaccines,
recombinant virus vaccines and dendritic cell vaccines. The identification of several differentiation
antigens such as gp100 and MART-1 paved the way for the development of cancer vaccines.
Additional tumour antigens used in cancer vaccines include overexpressed antigens (Mesothelin),
viral antigens (HPV E6, E7), cancer-testis antigens (MAGE family) and neo-antigens (Ras )(110,
111). Although the success of cancer vaccines has been limited, the results from pre-clinical and
clinical studies thus far have provided insight into how their therapeutic efficacy can be improved.
For example, results from a standalone phase II study in which patients with metastatic melanoma
were treated with the gp100 peptide followed by Interleukin 2 (IL2) resulted in a 42% objective
clinical response providing evidence that vaccines could provide therapeutic benefit for cancer
treatment. A follow up randomized phase III study where patients received either gp100 alone or
gp100 followed by IL2 indicated that addition of IL2 provided additional benefit over gp100 alone
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as there was a significant improvement in the overall clinical response (36). These studies not
only showed the potential of cancer vaccines but the ability to be potentiated by adding additional
agents. As such, studies geared towards improving cancer vaccines via finding the right adjuvants
and immunopotentiators are underway(112).
Cytokine therapy
Cytokines are small proteins secreted by cells with a specific effect on the communication and
interaction between cell types. The two most common cytokines used for cancer treatment are
Interferon alpha (IFN-α) and IL2. IFN-α, a type I interferon, is produced by T cells, DCs, natural
killer cells and macrophages. In addition to directly inducing apoptosis in tumour cells, IFN-α also
stimulates anti-tumour innate and adaptive immune responses. Although the results regarding the
overall survival outcomes of IFN-α therapy in clinical studies are controversial, studies indicate
that IFN-α can provide disease free survival benefit when used in an adjuvant setting. However
IFN-α therapy can produce substantial toxicities in patients undergoing treatment (113-116). The
FDA approved cytokine IL2, was the first interleukin to be identified and cloned. This glycoprotein
is mainly produced and secreted by T helper cells, although it can also be produced by activated
CD8 T cells. IL2 has pleiotropic effects on several subsets of immune cells. It is vital in the
differentiation, proliferation and survival of T cells, as well as promoting the production of
immunoglobulins by B cells, boosting activation and proliferation of natural killer (NK) cells(117).
Because of its role in the promotion of the activation, expansion and survival of CTLs and NK
cells, IL2 has been used as a cancer therapy for quite some time. High dose IL-2 induces a 15%
response rate leading to a 5% cure of patients with metastatic melanoma(118). Therefore, was
one of the first-line treatment options for metastatic melanoma. It is has also improved the
therapeutic outcome when used in combination therapies with other immunotherapies such as
adoptive T cell therapy and cancer vaccines(119). Other cytokines with promising therapeutic
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benefit in cancer treatments include GM-CSF, IL21 and IL15. Clinical trials of evaluating their
therapeutic efficacy underway.
Adoptive cellular therapy
Preclinical murine syngeneic tumour models revealed the presence tumour infiltrating
lymphocytes (TIL). This discovery lead to the development of adoptive cellular therapy (ACT)
which involves isolation or engineering of T cells, ex vivo expansion and transfer of these T cells
back into patients(120). In one form of ACT TILs are isolated from resected tumour masses of
patients, expanded ex vivo and re-infused back into patients. In the early years, the clinical
responses to ACT were not encouraging. An overall objective response rate of 31% with a
complete response rate of only 5.8% was observed in a clinical study where 86 patients with
metastatic melanoma received autologous TILs followed by high dose IL2. To improve ACT,
follow up studies employed lymphodepletion which eliminated endogenous lymphocytes,
decreased competition for homeostatic cytokines and growth factors, and elimination of
immunosuppressive cells (36). The objective response rate observed when patients with
metastatic melanoma receiving either 2gy or 12gy total body irradiation was 52% and 72%
respectively with a complete response rate of about 22% indicating the potential of ACT as an
effective therapy for late stage melanoma. Although the results obtained with ACT are exciting,
there are still many challenges that need to be overcome. For one, it is still unclear what the
antigen specificity of TIL is and what percentage of TILs recognize the tumour. Thus, there may
be expansion of non-tumour reactive or bystander TILs decreasing the effectiveness of therapy.
In addition, the tumour environment can be quite immunosuppressive which could affect migration
and the persistence of TILs in vivo. Moreover, recent studies indicate the quality of TILs infused
could be improved as far as their differentiation status which could in turn affect the effector
function and persistence of TILs in vivo. Finally, the process itself is expensive, technically
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challenging and labor intensive. Notwithstanding, preclinical and clinical studies are currently
ongoing to evaluate multiple strategies to improve ACT.
One strategy to overcome the antigen specificity limitation is to genetically engineer
autologous TILs or peripheral blood mononuclear cells (PBMCs), via retroviral or lentiviral
transductions, to express tumour associated antigen (TAA) specific TCRs. As described earlier,
TCRs recognize antigens in the context of MHC or the human homolog, human leukocyte antigen
(HLA). Because TAAs are ‘self’ antigens, their naturally occurring TCR affinities are quite weak
as a result of thymic selection. Therefore, these TCRs are usually modified in vitro to confer higher
binding affinity(121). The most advanced examples of engineered high affinity TCRs against
TAAs, are the HLA-A*0201-restricted MART1 and HLA-A*01-restricted MAGE-A3 TCRs (120,
122, 123). Despite an encouraging clinical response of about 30% observed melanoma patients
treated with the MART1 TCR, majority of the patients experienced severe off target toxicities in
melanocytic expressing sites such as the ears, eyes and skin. Most severely, the first two patients
that received the MAGE-A3 TCR expressing T cells died from cardiogenic shock as a result of
the TCR recognizing an unrelated MAGE-A3 protein expressed by normal cardiac cells. These
results raise a concern of unwanted cross reactivity due expression of target antigen on normal
tissue. Nonetheless, cancers which express certain antigens, such as cancer testis antigens
(CTA) may benefit the most from this therapy since these antigens are highly in multiple tumour
types but not in normal adult tissue. While TCR expression favours generation of antigen specific
T cells not restricted to TILs, there are still some hurdles to overcome. For one, HLA expression
is heterogeneous amongst patients with the same cancer type, hence the engineered TCR may
only be applicable to a limited number of patients with the same HLA type. Moreover, as a
mechanism of immune escape, tumours are known to downregulated HLA expression rendering
themselves invisible to T cells.
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To circumvent HLA-restricted antitumour reactivity of T cells, T cells can be engineered
to express chimeric antigen receptors (CARs). CARs combine the antigen specificity of antibodies
with the cytotoxicity and survival of T cells such that, CAR-T cells recognize and kill tumour cells
independently of HLA. First created in the 1980s, the first generation of CARs were constructed
by linking the single-chain variable fragment (scFv) of a monoclonal antibody to the intracellular
TCR signaling domain CD3- ζ(124). Results from initial clinical trials with CAR-T cells were not
very encouraging characterized by mediocre expansion and survival of transferred CAR-T cells
in vivo(125). Subsequent studies lead to the development of second and third generation CARs
which included one or two co-stimulatory domains in addition to the aforementioned components,
greatly enhancing CAR- T cell persistence in vivo(120). Till date, the most successful CAR is the
CD19 targeting CAR in patients with B-cell malignancies. Similar to TCR engineered T cells, the
expression level of targeted antigens on normal cells is crucial to limiting toxicity of CAR-T cells.
In addition, both treatment modalities usually target a single antigen favouring tumour escape.
Therefore, evaluations of bispecific CARs or combination of CARs with varying antigen specificity
to prevent antigen escape are ongoing
As mentioned above one important limitation of ACT is that efficient migration of
transferred TILs into the tumour bed is quite lacking. While clinical studies, using indium-111
labelled TILs, indicate that the number of adoptively transferred TILs migrating into the tumour
positively correlates with clinical response(126), the trafficking efficiency of TILs can be
tremendously mediocre(127). One important aspect of T cell trafficking is the ability to localize to
infection sites or tissues along a chemokine gradient. In the case of an anti-tumour response, this
process is enabled by expression of the appropriate chemokine receptors on T cells to facilitate
localization to the tumour milieu expressing the corresponding chemokines. Evaluation of human
melanoma tumours revealed a preferential expression of high levels of the chemokines CXCL1
and CXCL8, hence a bias towards high levels of monocyte/macrophage lineage infiltrates which
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highly express CXCR2, the receptor to these chemokines (63, 128, 129). Borrowing a leaf from
nature’s book, investigators overexpressed CXCR2 in adoptively transferred T cells in preclinical
murine studies and showed that this greatly enhanced the migration of adoptively transferred T
cells into the tumour, leading to enhanced tumour regression(130). Clinical trials to evaluate this
improvement are currently ongoing.
Finally improving the persistence and effector function of adoptively transferred TILs is
crucial to improving ACT. I will expand on this topic in chapter 3.
Immune checkpoint therapy
In order to sustain an antitumour immune response, the co-receptor content in the context
of T cell activation is very crucial. The tumour microenvironment could be quite a suppressive
milieu, with the tumour cells themselves and myeloid derived suppressive cells (MDSCs)
expressing the ligands to co-inhibitory receptors, thereby dampening T cell activation. An
understanding of the importance of co-stimulatory and inhibitory pathways has led to the clinical
development of modulatory antibodies targeting these receptors in order to sustain anti- tumour
immune responses. In the case of co-stimulation, agonistic antibodies to the co-stimulatory TNFreceptor superfamily members 4-1BB and OX40 are the farthest along in clinical trials. While,
blocking antibodies to co-inhibitory receptors CTLA4 and PD1, have been FDA approved for the
treatment of multiple cancer types. I will expand upon the latter below.
Anti-CTLA4
The co-inhibitory receptor, Cytotoxic T-lymphocyte antigen (CTLA)-4, a member of the
immunoglobulin (Ig) superfamily. Located on human chromosome 2q33 and mouse chromosome
1, CTLA4 is exclusively expressed on T lymphocytes (131). Unlike CD28, CTLA4 expression on
T cells is activation induced (132). As such activated but not naïve T cells express CTLA4.
Following TCR activation on conventional T cells, CTLA4 is sequestered from intracellular trans-
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golgi network compartments to the immune synapse where it binds competitively to its ligands
CD80 and CD86 on APCs with stronger affinity over its co-stimulatory Ig family member CD28
(133). Unlike CD28, CTLA4 binding inhibits IL2 secretion, induces cell cycle arrest and
downregulates T cell activation. While the mechanism of action of CTLA-4 is still under debate, it
is thought CTLA4 outcompetes CD28 for the ligands CD80/CD86 thereby preventing positive
signaling. In addition, CTLA4 recruits the phosphatases, SHP2 and PP2A, to the immune synapse
which subsequently dephosphorylate key signaling components such as ZAP70 downstream
TCR activation (134, 135). Moreover, CTLA4 can confer T cell inhibition through the sequestration
of CD80 and CD86 from CD28 engagement, as well as active removal of CD80 and CD86 from
the APC surface.
In contrast to conventional T cells, CTLA4 is constitutively expressed on T regulatory cells
(Tregs). CTLA-4 is a target gene of the forkhead transcription factor 3 (FOXP3) and can contribute
to the suppressive ability of Tregs. There have however been conflicting in vitro and in vivo reports
in the field concerning the contribution of CTLA4 to Treg suppression. Sakaguchi and Powrie
provided initial evidence that the CTLA4 pathway could be used to elicit Treg suppression (136,
137). However, reports from early work performed by the Shevach group and others showed
failure to reverse Treg suppression following CTLA4 blockade in vitro (138). Subsequent studies
demonstrated that Tregs from CTLA4 deficient (CTLA4-/-) mice retained their suppressive
function in vitro(139). In some studies CTLA4-/- Treg suppressed slightly less efficiently than
wildtype Tregs, echoing the early observation that CTLA4-/- Tregs showed about 50%
suppression compared to about 95% suppression elicited by their wildtype counterparts(137).
Moreover, studies from Tang and colleagues indicated that even though CTLA4-/- Tregs were
capable of suppression, the function of wildtype Treg was abrogated by CTLA4 blockade(140).
This suggested that wildtype Tregs use CTLA4 to suppress but that compensatory mechanisms
develop in CTLA4 deficient animals. Suppressive compensatory pathways were elegantly
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demonstrated by the observation that a dual deficiency in IL-10 and IL-35 (suppressive cytokines
secreted by Tregs) results in a remarkable compensatory increase in TRAIL expression and
increased dependence on the TRAIL pathway for suppression in vitro. In in vivo settings, there is
now overwhelming evidence supporting a role for CTLA4 in Treg suppression(140). Particularly
key evidence that CTLA4 can physically remove its ligands CD80/CD86 from antigen presenting
cells by a process known as trans-endocytosis, providing a mechanism for Tregs to regulate
CD28 stimulation of other T cells.. All-in-all, the general consensus is that CTLA-4 plays a key
role in Treg function although other mechanisms can sometimes substitute in its absence.
Known as the godfather of immune checkpoints, CTLA4 was the first immune checkpoint
receptor to be targeted for the treatment of cancer, paving the way for targeting other immune
checkpoint receptors(131). Because of the lack of tumour specificity for the expression ligands of
CTLA4 on solid tumours, coupled with the fact that CTLA4 knockout (KO) mice displayed a hyperand autoimmune phenotype that was lethal, the general strategy of CTLA4 blockade was
unattractive. Nevertheless, reports from Allison and colleagues using preclinical models
demonstrated that partial blockade of CTLA4 using antibodies could provide a therapeutic effect
without overt immune toxicities(141).

Immunogenic tumours treated with CTLA4 blocking

antibodies as single agents, responded to treatment while poorly immunogenic tumours did not
respond unless combined with a granulocyte–macrophage colony stimulating factor (GM-CSF)transduced cellular vaccine. In addition, CTLA4 blockade lead to the depletion of Tregs from the
tumour microenvironment, coupled with an increase in the expression of the co-stimulatory
molecule ICOS on TILs. These findings suggested that, CTLA4 blockade could enhance
endogenous antitumour immune responses, which ultimately can induce tumour regression.
Based on these preclinical findings, two fully humanized antagonistic CTLA4 antibodies,
ipilimumab and tremelimumab, were produced and clinically evaluated beginning in the year
2000. As single agents both antibodies produced objective clinical responses in ~10% of patients
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with metastatic melanoma (142-144). However, immune-related toxicities involving various tissue
sites, particularly colitis, were observed in about 25–30% of patients. In a randomized Phase III
clinical trial, patients with advance melanoma were treated 15mg/kg of tremelimumab, given every
three months as a single agent and compared with dacarbazine a standard melanoma
chemotherapy agent(145). No survival benefit, with this dose and schedule relative to
dacarbazine, was observed in this trial. However, ipilimumab was more carefully evaluated at
different doses and schedules, in addition to clinical management of the immune related toxicities
using steroids and TNF blockers (146). Finally, in a randomized phase III three-arm clinical trial,
metastatic melanoma patients received either: the gp100 vaccine, the gp100 vaccine plus
ipilimumab, or ipilimumab alone. A survival benefit of 3.5 month was observed for patients in both
groups receiving ipilimumab, compared to the group receiving the gp100 vaccine alone (147). As
the first therapy to exhibit a survival benefit for patients with metastatic melanoma, ipilimumab
was approved by the US Food and Drug Administration (FDA) for the treatment of advanced
melanoma in 2010. Much more impressive than the mean survival benefit was the long term
survival effect of ipilimumab. Compared with a long term survival of 5% of patients receiving the
gp100 vaccine alone, 18% of the ipilimumab-treated patients survived beyond two years. This
benefit of ongoing long term responses and survival well after completion of a relatively short
course of therapy support the notion that T cell based immune therapies re-educate the immune
system to keep tumours in check following therapy completion. Nonetheless, as with most
oncology agents that provide benefit to a limited proportion of treated patients, much effort must
be expended to define biomarkers predictive clinical responses.
Anti-PD1/Anti-PDL1
Programmed death 1 (PD1) is another co-inhibitory receptor expressed on activated T cells, B
cells, natural killer cells and macrophages. The known two ligands for PD1 are PD1 ligand 1
(PDL1) and PDL2 expressed on a variety of immune cells. PDL1 and PDL2 are also highly

39

expressed on some tumour types, although they can also be upregulated on tumour cells by IFN. Unlike CTLA4, PD1’s major role is to limit the activity of T cells in peripheral tissues at times of
an inflammatory response to infection and as well as to limit autoimmunity. PD1 therefore,
predominantly regulates effector T cell functions within tumours and tissues, while CTLA4
predominantly regulates T cell activation. The binding of PD1 to PDL1/PDL2 results in the
phosphorylation of two tyrosine residues in the intracellular tail of PD1(148). These tyrosine
residues are part of an immunoreceptor Tyrosine-based Inhibitory Motif (ITIM) and an
Immunoreceptor Tyrosine-based Switch Motif (ITSM). ITSM then recruits either of two SH2domain containing protein tyrosine phosphatases, tyrosine phosphatase 1 (SHP-1) and SHP-2.
SHP-1 and SHP-2 then suppress activation of PI3K/Akt pathway(149). As a result, the expression
of the pro-survival molecule Bcl-xL is decreased and expression of transcription factors
associated with effector function including GATA-3, T-bet and Eomes are lost(149-151). The end
result is diminished effector function in T cells characterized by decreased cytokine production,
cytolytic function, and survival. PD1 is also highly expressed on Tregs, where it may enhance
their proliferation in the presence of ligand in addition suppression of effector immune responses.
Generally, the PD1 pathway is thought to be mediate immune evasion in a process known
as termed as “adaptive resistance”(131, 152). This stemmed from observations of PDL1 being
absent from most normal tissues, whereas PDL1 can be induced by in practically any nucleated
cell (153-156). Since hematopoietic cells are the main source of IFN-, it is reasonable to suggest
that PDL1 expression could be induced as a result of cancer-induced inflammation. Tumour
antigens can be presented to TILs by tumour cells, stromal cells as well as APCs. Following
antigen stimulation TILs release IFN- leading to PDL1 induction in the tumour milieu. IFN-
release can be a double edged sword. While IFN- enhances antigen processing and presentation
as well as TIL differentiation, upregulation of PDL1 can also dampen T cell effector functions (157159).

Consequently, though the physiological role of PDL1 is to limit tissue damage via
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dampening inflammation, PDL1 induction in the tumor microenvironment serves as a negative
feedback mechanism to suppress T cell mediated antitumour immunity. This premise is supported
by studies in melanoma showing a strong correlation between PDL1 expression in human
melanocytic lesions and the presence of TILs. Laser-capture microdissection and quantitative real
time PCR of tumour slides enabled the detection of IFN- at the interface of TILs and PDL1
expressing cells (157). Whereas IFN- remained undetectable within PDL1 negative tumour
sections. Moreover, in murine tumour models, IFN- neutralization via administration of anti-IFN antibodies abrogated PDL1 upregulation in the tumor microenvironment, demonstrating that
IFN- is a major inducer of PDL1 in vivo(160). As such, PDL1 greatly contributes to the
mechanisms of adaptive resistance shedding some light on immune evasion by cancer cells,
despite endogenous tumour reactive T cells. Notably, cancer cells are also know to express PDL1
via IFN- independent mechanisms, as a small fraction of human cancers express high levels of
PDL1 but lack TILs in the tumor microenvironment. There is now increasing evidence that tumour
intrinsic oncogenic signaling may drive PDL1 expression. Several studies have revealed that
aberrant EGFR, ALK and PI3K (via PTEN loss) signaling can directly upregulate PDL1 on cancer
cells(160-162).
In NSCLC, renal cell carcinoma and metastatic melanoma, Nivolumab was the first
monoclonal antibody (mAb) targeting PD1 to show significant clinical activity and is FDA approved
for the treatment of both advanced melanoma and squamous NSCLC. In multiple melanoma
clinical trials, Nivolumab has consistently induced objective response rates (ORR) of up to 40%
in treated patients(163-166). Furthermore, in metastatic squamous NSCLC patients, Nivolumab
also extended overall survival compared with standard chemotherapy. Moreover a recent phase
I study evaluating the treatment of relapsed or refractory Hodgkin’s lymphoma nivolumab
produced an ORR as high as 87%(167). Nivolumab has also been used in combination therapy
with ipilumumab. The overall survival of patients with advanced melanoma on a concurrent
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regimen of nivolumab and ipilimumab was 94% after one year (NCT01024231). Pembrolizumab,
another antagonistic mAb targeting PD1, has shown similar efficacy and safety compared with
nivolumab in a phase I clinical trial in advanced melanoma (168, 169). It is now an FDA approved
as a second line treatment for melanoma. In several clinical trials pembrolizumab has been
effective in patients with advanced NSCLC, advanced gastric cancer, advanced bladder cancer,
head and neck cancer, classical Hodgkin’s lymphoma, and triple-negative breast cancer(152,
170-172). Monoclonal antibodies targeting PDL1 have also been developed and shown to be
have therapeutic benefit in advanced human cancers. They include MDX-1105 (BMS) and
MPDL3280A (Genetech/Roche), Pidilizumab (Medivation/ CureTech), MEDI4736 (AstraZeneca)
and Avelumab (Merck-Sorono)(152). While PDL1 expression can to a degree be predictive of
response to anti-PD1/PDL1 therapy, there are patients whose tumours express PDL1 but do not
respond to these therapies and vice versa. This begs the need for continued investigation of these
pathways as well rationale combinations with other therapies to provide better and longer lasting
outcomes for cancer patients.
In summary, T cell mediated antitumour immune responses are regulated by delicate
molecular interactions between T cells and the tumour microenvironment. A number of attractive
negative regulatory mechanisms that limit the function of tumour reactive cells have been
identified. Several prospective clinical trials based on these immunosuppressive mechanisms
have been carried out. However, the expectations of these promising treatments have not
translated into clinical success for all cancer patients suggesting that the list of tumour-associated
negative immunregulators is incomplete. Understanding these regulatory mechanisms is not only
important from an academic viewpoint, but can also provide strategies for the development of
new and/or improved immunotherapy treatments against cancer.
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Figure 1: The three signal model of T cell activation
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Figure 2: Co‐stimulatory and co‐inhibitory molecules and their respective ligands
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Chapter 2
Enhancing T cell mediated anti-tumour immunity via HSP90
inhibition
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Abstract
T cell-based immunotherapy has a major impact for cancer patients. However, the vast
majority of patients do not benefit from these therapies. With increasing evidence that tumour
intrinsic pathways modulate responses to immunotherapy, targeting these pathways provide a
promising strategy for improving the efficacy of immunotherapy agents. Therefore, we made
considerable efforts to investigate novel potential combinatorial targeted agents with
immunotherapy using preclinical models. For this purpose, I used multiple paired patient-derived
melanoma cell lines and their autologous TILs in a novel high-throughput chemical compound
screen platform to identify compounds that improved the sensitivity of tumour cells to T cell killing.
We hypothesized that these identified compounds could be used in combination with
immunotherapy and improve the therapeutic antitumour outcomes when compared with the
single-agent immunotherapy approach.
We successfully identified HSP90 inhibitors as agents that potentiate responses to T cell
based immunotherapy by using this established platform to screen 850 compounds. In vitro
studies we show that HSP90 inhibition synergistically improves T cell killing of multiple patientderived human melanoma cell lines. Subsequently, we show that the clinically-relevant HSP90
inhibitor ganetespib potentiated responses to anti-CTLA4 and anti-PD1 immunotherapy in a
preclinical murine tumour model. Mechanistically, upregulation of interferon response genes in
the tumour cells, as a result of HSP90 inhibition, is essential for the enhanced T cell-mediated
killing of tumour cells. These results not only highlight the therapeutic potential of HSP90 inhibition
plus immune checkpoint blockade in cancer treatment, but also provide further supporting
evidence of the essential role of interferon response genes in inducing death of tumour cells and
their importance in potentiating response to T cell-mediated immunotherapy. Based on these
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results, translation of the combination of HSP90 inhibitors and immunotherapy to the clinic is
being actively pursued.

Tumour-intrinsic oncogenic pathways/proteins that interfere with response to T cell based
immunotherapy
Over the years, the hallmarks of cancer described by Hanahan and Weinberg have been well
supported and established by numerous studies. One of the original hallmarks of cancer
described is the sustained proliferative ability of tumour cells driven by tumour intrinsic oncogenic
signaling(173). There is now increasing evidence that tumour intrinsic oncogenic signaling not
only promotes tumourigenesis but also contributes to immune evasion. It is no surprise therefore
that some therapies targeting these oncogenic proteins have underlying immune mediated
therapeutics effects and depletion of CD8 T cells results in abrogation of their therapeutic effect.
In addition, inhibition of these tumour intrinsic signaling pathways can also lead to improved T cell
responses including increased T cell trafficking and T cell mediated killing of tumour cells. In this
section I will review some of the emerging tumour intrinsic oncogenic pathways that contribute to
decreased or non-responsiveness to T cell mediated immunotherapy.
BRAF
BRAF is a component of the RAS-RAF-MEK-MAPK signal transduction pathway which is a critical
regulator of cellular growth and survival. Till date, over 50 distinct activating point mutations have
been identified the BRAF gene(174). The most common mutation described is a valine to glutamic
acid substitution at amino acid position 600(V600E). It is by far the most frequent BRAF mutation,
comprising more than 70% of BRAF mutations in melanoma (175, 176). BRAF is also mutated to
a constitutively activated form in many other cancers types, including hairy cell leukemia, thyroid
and colorectal (177). The wide expression of BRAF (V600E) mutation prompted the development
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and clinical application of small-molecule–based pharmaceutical inhibitors selectively targeting
BRAF (V600E) for the treatment of patients with metastatic melanoma (178). Although robust
tumour regression is observed in more than half patients treated with the BRAF inhibitor
vemurafenib, the development of resistance can sometimes occur (178, 179). As such,
combination therapies with immune therapies is an attractive alternative to single agent treatment
with multiple studies linking of MAPK activation with immunosuppression. For instance, studies in
melanoma, have shown that the development of resistance to BRAF inhibitors is usually
accompanied by upregulation of PDL1 on melanoma cells (180). In addition, oncogenic BRAF
signaling in tumour cells results in the expression of immunosuppressive molecules such as
VEGF, IL6 and IL10 in the tumour microenvironment and knockdown of BRAF significantly
decreases secretion of these cytokines (181). In vivo studies also showed that inhibition of BRAF
decreased VEGF production by tumour cells leading to an increase in the infiltration of T cells into
the tumour(182). Finally, BRAF inhibition or blocking of MAPK signaling in melanoma cells
augments antigen presentation, leading to improved recognition of treated cells by antigen
specific T cells significantly (183-185).
Wnt/β-catenin
The Wnt family of genes encodes 19 secreted glycoproteins which are ligands to receptormediated signaling pathways controlling cell fate and differentiation, cell proliferation, and cell
motility(186). In canonical Wnt signaling, a Wnt protein binding to a member of the Frizzled (frz)
transmembrane receptor family and initiates a Wnt signaling cascade. This leads to
hyperphosphorylation of the Dishevelled protein (dsh) which then prevents the phosphorylation
of β-catenin by the degradation complex (GSK-3, APC, and Axin)(187). Stable β-catenin then
interacts with lymphoid enhancer factor/T cell factor (Lef/Tcf) and is translocated into the nucleus
as a complex to stimulate target gene transcription. Noncanonical Wnt signaling, uses β-cateninindependent signaling mechanisms. The Wnt pathway has been implicated in multiple cancer
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types. Particularly, gain of function mutations in β-catenin and loss of function mutations in
negative regulators (such as TCF1, GSK-3, APC, and Axin) that lead to constitutive activation of
Wnt/β-catenin signaling(188) . In a recent melanoma study from Spranger et al, gene expression
profiling was done on melanoma tumours that were classified as either T cell inflamed (had T
cells infiltrates and associate genes) or non-T cell-inflamed(189). About 48% of non T cell
inflamed tumours had aberrant activation of the Wnt/β-catenin pathway. Follow up in vivo studies
employed the use of spontaneous melanoma genetic models with stabilized β-catenin to decipher
the importance of aberrant tumour-intrinsic β-catenin signaling in an anti-tumour immune
response. In this model Spranger and colleagues found that these melanomas completely lacked
tumour infiltrates. In addition, anti-PDL1 and anti-CLTA4 treatments had no therapeutic effect in
this model. Finally, closer examination of these tumours showed a deficiency in CD103/CD8α
expressing DCs due to a defect in the production of the chemokine CCL4, which is critical in
recruiting these cells. This study provides evidence of an oncogenic tumour intrinsic pathway that
not only inhibits the generation of an anti-tumour response but also mediates resistance to
immune checkpoint blockade therapy.
PI3K/PTEN/AKT
The Phosphoinositide 3-kinases (PI3K) pathway is an important pathway that generates
phosphorylated intracellular lipids that affect a range of cellular activities including proliferation
and survival. PI3K is regulated by the tumour suppressor gene PTEN which dephosphorylates
activated lipids attenuating signaling(190).

Over the years, several studies focused on

inflammation-induced cancer progression have identified activating aberrations in PI3K signaling,
either loss of function mutations in PTEN through or activating mutations in PIK3CA(191). The
resulting suppressive tumour microenvironment was associated with an increase in
immunosuppressive cytokines VEGFA, IL8, IL6, CSF1 accompanied by increased accumulation
of tumour-associated macrophages. In addition, a recent study in melanoma by Peng and
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colleagues also implicated PTEN loss in resistance to immunotherapy(192). Tumours with loss of
PTEN protein expression had decreased infiltration of CD8 T cells in both BRAF/NRAS wild type
and BRAF-mutant melanomas. Furthermore, analysis of samples collected from treated patients
revealed that low PTEN expression is associated with reduced LCK expression, Lscore, and
cytolytic activity in melanomas, consistent with decreased immune infiltration with PTEN loss.
Moreover, PTEN deletions and loss of function mutations were also considerably enriched in the
non-T cell–inflamed tumours in the melanoma TCGA samples. In anti-PD1 treated patients PTEN
loss was found to be enriched in non-responders compared to responders. In addition, decreased
T cell infiltration into tumours and PTEN loss also contributed to decreased T cell mediated lysis
of tumours(193). Notably, these analyses of the melanoma TCGA provided support that loss of
PTEN in melanomas is largely mutually exclusive with β-catenin pathway alterations. These
provide evidence that multiple distinct genetic events can give rise to immune exclusion.
Nevertheless, oncogenic activation of the Wnt/β-catenin and PI3K pathways do not account for
all of the tumours with the non-T cell–inflamed phenotype, suggesting that additional pathways
exist that contribute to immune exclusion warranting further exploration.
HSP90
HSP90 biology
Heat shock protein 90 (HSP90) is a molecular chaperone whose role is to properly fold over 200
client proteins thereby maturing, stabilizing, regulating and activating their function. Higher
eukaryotes possess several isoforms of HSP90 located in the cytoplasm, mitochondria and
endoplasmic reticulum. HSP90α, inducible under stressful conditions, and HSP90β, which is
constitutively expressed, are the two major cytoplasmic isoforms. While, GRP96 is expressed in
the endoplasmic reticulum and TRAP-1 in the mitochondrial matrix (194-196). HSP90 structurally
consists of a homodimer, with each protomer having three functional domains: An ATP binding
N-terminal domain (N-domain), a middle domain (M-domain) and a dimerizing C-terminal domain
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(C-domain) (Figure3)(197). All three domains provide co-chaperon and client protein binding
sites. Interaction of HSP90 with its plethora of client proteins is facilitated by co-chaperons that
serve as adaptor molecules providing selectivity and specificity for client proteins. Over 20 cochaperons have been identified to date and in addition to recruiting specific client proteins, they
activate or inhibit the HSP90 ATPase. Usually, different co-chaperons work together to enable
client protein maturation. Thus, co-chaperon complexes are to a certain extent dictated by specific
client proteins. All-in-all the proper folding of a client protein requires assembly of an HSP90
complex consisting of the client protein, co-chaperons and HSP90(198).
The HSP90 chaperone cycle is a tightly regulated process including multiple steps (Figure
4). It begins with the assembly of an ‘early complex’ involving association of a client protein with
an HSP70/HSP40 complex. The co-chaperon Hop then facilitates interaction of the early complex
with HSP90 and transfer of the client protein to HSP90 to form an ‘intermediate complex’.
Depending on the client protein additional co-chaperons can be recruited to facilitate this transfer.
ATP binding recruits additional co-chaperons that stabilize the HSP90 complex and promote
release of the Hop and HSP70 from the complex. ATP hydrolysis induces conformational changes
that enable folding of the client protein and leads to release of folded protein ADP and cochaperons completing the cycle(198).
Over the years, a broad spectrum of over 200 HSP90 client proteins have been identified.
These encompass many protein classes including steroid hormones, protein kinases,
transcription factors, RNA polymerases, PI3 kinase-like kinases and NLR receptors, amongst
others (199-201). Many known oncoproteins such as BRAF, HER2, EGFR, BCR-ABL and MET
are client proteins of HSP90, thereby affirming the importance of HSP90 in tumour growth,
survival, invasion and metastasis (Figure 5). It is thought that the instability of these proteins
caused by mutations, coupled with environmental stress and genetic instability, produce a great
dependency of tumour cells on HSP90. Therefore, the number of HSP90 complexes found in

51

tumour cells are up to 10 fold higher than those found in normal cells. This phenomenon has
attracted the use of HSP90 inhibitors in cancer treatment, as inhibition of HSP90 promotes
concurrent inhibition of multiple oncogenic pathways.
HSP90 inhibitors in cancer treatment
The first two HSP90 inhibitors developed were the two natural products, geldanamycin
(GM) and radicicol (RD)(202, 203). Both compounds were found to inhibit HSP90 via competitive
binding with ATP to its N-terminal regulatory pocket. However, these two compounds were not
clinically relevant given their poor stability and toxicities in vivo, stemming from their reactive
chemical structures. Nevertheless, these molecules served as pathfinder and tools for better
understanding HSP90 biology in tumours. They also provided valuable pharmacophores for nextgeneration inhibitors (Figure 6). The first generation HSP90 inhibitor compounds were derivatives
of the antibiotic, GM, created by substituting the non-essential C-17 methoxy group on the
bezoquinone moiety with various amines. 17-N-allylamino-17-demethoxygeldanamycin (17-AAG)
was the first of its kind to enter clinical trials (204). While 17-AAG (tanespimycin) retained the
important biological features of GM, it had an improved toxicity profile (205). Various dosing
schedules and formulations, as a single agent therapy, were explored in divers Phase I clinical
trials with the most promising clinical activity observed being stable disease (SD). In Phase II trials
in melanoma, prostate and renal cell cancer, no objective responses were noted with single agent
tanespimycin despite the presence of known target client proteins in these cancers (206, 207).
On the other hand, in a Phase II trial of tanespimycin in combination with trastuzumab in HER2+
metastatic breast cancer (MBC) patients progressing on prior trastuzumab, an overall response
rate (ORR) and clinical benefit rate (CBR) of , 22% and 59%, respectively was observed(208).
The median progression free survival (PFS) and overall survival (OS) were 6 and 17 months,
respectively. This indicated that efficacy could be obtained in a combination setting as well as
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with patient enrichment (HER2 is a client protein sensitive to the HSP90 inhibitor). Nevertheless,
due to poor a pharmaceutical and toxicity profile, 17-AAG failed to advance further.
17- desmethoxy-17-N,N-dimethylaminoethylaminogeldanamycin (17-DMAG) developed
by Kosan Biosciences overcame the solubility issues observed with 17-AAG (203). Instead of the
methoxy group at C-17, 17-DMAG contains the ionizable N,N-dimethylethylamine group which
provided the much-needed improvement in water solubility, oral bioavailability and equal, if not
greater, antitumour activity than 17-AAG. In 2004, 17-DMAG (alvespimycin) was investigated in
clinical trials both as an oral and intravenous agent (207, 209-211). In patients with castrateresistant prostate cancer (CRPC), acute myeloid leukemia, clear cell renal cancer and metastatic
melanoma objective responses, including some CRs, were observed (210-212). In addition, SD
greater than 6 months were also reported in 3 patients with chondrosarcoma, CRPC and clear
cell renal cancer. Toxicities such as diarrhea, fatigue, nausea, liver, lung, ocular and cardiac
toxicities reported in these trials. Comparable to tanespimycin, a phase I clinical trial indicated
that alvespimycin may be most beneficial in combination with trastuzumab. In this trial a PR in a
HER2+ MBC patient and SD lasting longer than 6 months in 6 of the 28 other patients was
observed with the combination of alvespimycin and trastuzumab(203). However, the clinical
development of alvespimycin was halted in 2008 by Kosan due to strategic reasons, despite these
encouraging objective responses. However, alvespimycin is currently under evaluation by the
National Cancer Institute for the treatment of patients with relapsed small lymphocytic lymphoma,
B-cell prolymphocytic leukemia and chronic lymphocytic leukemia (CLL)(203).
In summary, research efforts by both academia and industry to develop newer HSP90
inhibitors with better bioavailability and toxicity profiles to provide increased therapeutic benefit
have been fueled by GM derivatives. The pursuit for these much-improved small synthetic
molecules resulted in the development of better HSP90 inhibitors known as second generation
HSP90 inhibitors. Studies with the first generation HSP90 inhibitors also informed what tumour
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subtypes more likely to benefit from HSP90 inhibitors facilitating the clinical path of upcoming
agents.
Ganetespib: a second generation HSP90 inhibitor
Ganetespib (STA-9090) a second generation HSP90 inhibitor with a prevalent triazolone moiety,
developed by Synta pharmaceuticals. This inhibitor has a considerably smaller unique scaffold
that distinguishes it from the first generation GM analogues (213). As reviewed above, the
chaperone activity of HSP90 is associated with ATP-driven conformational changes within the Nterminal domain. Due to their larger sizes, the GM analogues can only occupy the ATP-binding
pocket in the open conformation, whereas, ganetespib is able to enter the ATP-binding pocket in
the closed conformation due to its smaller size (214). The lack of binding restriction to the ATP
pocket contributes greatly to the higher in vitro potency of ganetespib compared to the GM
analogues. Till date, ganetespib has been or is currently being tested in over 25 clinical trials in
both hematologic and solid tumours. The dosing schedule for ganetespib was evaluated for solid
malignancies in two clinical trials: it was either given intravenously weekly for 3 weeks in a 28-day
cycle or twice-weekly dosing for 3 weeks in a 28-day cycle. Ganetespib was well tolerated in
patients with mostly grade 1 or 2 toxicities that were easily manageable. Following these studies,
200 mg/m2 was the recommended Phase II dose for the weekly dosing. One patient with
advanced melanoma achieved a PR while 2 with non-small cell lung cancer (NSCLC) achieved
SD (202, 203). Ganetespib was also evaluated in two Phase I single agent targeting hematologic
malignancies The recommended doses for further study in this population were 200 mg/m2 once
weekly and 90 mg/m2 twice weekly. The most common adverse events in both these trials were
mild-to-moderate diarrhea and fatigue that were reversible and easily manageable. Finally,
ganetespib was also evaluated in Phase I trials in patients with NSCLC, GIST and MBC. As a
single agent in advanced NSCLC, ganetespib showed encouraging activity in patients whose
tumours harboured an EML4-ALK rearrangement, were naïve for crizotinib treatment and were
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either a non-mutant EGFR or KRAS. Amongst eight such patients evaluated, there were four PRs
and a median PFS of 8.1 months. This provided a foundation for a Phase II study of ganetespib
monotherapy in patients with ALK-positive disease who were crizotinib-naïve. Supporting data
from preclinical studies showing synergistic antitumour effects provided rationale for combining
HSP90 inhibitors with taxanes. As such a randomized Phase II GALAXY-I trial combining
ganetespib with docetaxel, an extended OS was observed with ganetespib and docetaxel
compared to docetaxel alone in the second-line setting in patients with advanced NSCLC. This
trial encouraged a phase III trial of this combination in NSCLC known as the GALAXY-2 trial and
results are currently awaited (202, 203).
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Results
HSP90 inhibition enhances T cell mediated killing of melanoma cells
To identify compounds that increase the sensitivity of human melanoma cells to T cell
mediated killing, we utilized paired patient derived human melanoma cell lines and their
autologous tumour infiltrating T cells (TILs), derived from our active adoptive cell therapy program,
in a high throughput in vitro screen of 850 bioactive compounds. Two human melanoma cell lines
2549 (wild type for BRAF, NRAS and cKIT) and 2338 (BRAF V600E mutated) were treated with
1uM of each compound for 24 hrs or DMSO as a control. The treated tumour cells were then
washed and incubated with autologous TILs for 3hrs at a predetermined ratio, and the levels of
cleaved caspase 3 assessed as a readout of apoptosis. To quantify the interactive effect of the
compounds on T cell mediated killing, a comboscore was calculated from the percentage of T
cell–induced apoptosis in tumour cells with or without compound treatment. Compounds that
enhance the sensitivity of tumour cells to T cell mediated killing have comboscores >1. Amongst
the top candidates that increased the sensitivity of treated tumour cells to T cell killing were all
three HSP90 inhibitors in the screen: 17-DMAG, BIIB021 and 17-AAG (Figure 7A and
Supplemental Figure 1A). To validate these findings, we utilized a newer generation HSP90
inhibitor, ganetespib, which has been reported to exhibit greater potency in preclinical tumour
models and reduced toxicity in rodents compared to other 1st and 2nd generation HSP90 inhibitors.
Additionally, ganetespib also has a comparably better safety profile in patients (202, 215).
Confirming the screen results, varying concentrations of ganetespib increased the sensitivity of
2549 and 2338, and additional human melanoma cell lines 2400 and 2559 (BRAF V600E
mutated), to T cell mediated killing (Figure 7B and Supplemental Figure 1B). Furthermore, the
combination of ganetespib and TIL treatment was formally synergistic in tumour cell killing,
especially at lower concentrations of ganetespib, as indicated by combination indexes (CI) < 1
(Figure 7C and Supplemental Figure 1C) calculated by the Chou-Talalay method(216). Taken
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together, these data suggest HSP90 inhibitors as a combination partner to improve response to
immunotherapy.

The IFIT genes are essential for the enhanced T cell killing of tumour cells following HSP90
inhibition
To mechanistically understand how HSP90 inhibition increased sensitivity of tumour cells
to T cell killing, we performed gene expression analysis of the human melanoma cell lines 2400,
2338, 2549 and 2559 treated with either DMSO, as a control, or ganetespib alone. Two commonly
used bioinformatics tools, gene set enrichment analysis (GSEA) and Ingenuity Pathway Analysis
(IPA), both implicated interferon response genes as being significantly upregulated following
treatment with ganetespib, with interferon signaling being the highest-scoring canonical pathway
by IPA (Supplemental Figure 2A-C and Figure 8A). Upregulation of interferon response genes in
multiple melanoma cell lines by ganetespib was confirmed by quantitative real time PCR and
Western blot analyses, most strongly for members of the IFN-induced protein with
tetratricopeptide repeats (IFIT) gene family: IFIT1, IFIT2 and IFIT3 (Figure 8B-C & Supplemental
Figure 4A-B). Furthermore, the IFIT genes were upregulated in vivo following treatment with
ganetespib (Supplemental Figure 3). To determine the importance of the IFIT genes in the
synergy observed between ganetespib treatment and T cells in tumour cell killing, IFIT gene
expression was perturbed in tumour cells. IFIT-silenced and control tumour cell lines were
generated by simultaneously transducing tumour cells with IFIT1, IFIT2 and IFIT3 small hairpin
RNAs (shRNA) or with scrambled shRNA, respectively (Figure 9A and Supplemental figure 5A).
DMSO treated control and IFIT-silenced cell lines were equally sensitive to T cell killing. However,
silencing the IFIT genes abrogated the enhanced killing of the melanoma cells potentiated by
ganetespib (Figure 9B and Supplemental Figure 5B). Conversely, overexpressing IFIT1, IFIT2
and IFIT3 in human melanoma cell lines enhanced the sensitivity of human melanoma cell lines
to T cell killing, thereby recapitulating the effects of ganetespib treatment (Figure 9C-D and
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Supplemental Figure 5C-D). Interrogating apoptotic molecules upstream of caspase 3 revealed a
dramatic decrease in BCL2 expression following overexpression of the IFIT genes (Figure 9E &
Supplemental Figure 5E), suggesting that the IFIT genes promote sensitivity to apoptosis of the
tumour cells. Taken together, our studies indicate that upregulation of IFIT genes is essential for
the enhanced T cell killing of melanoma cells following HSP90 inhibition.

HSP90 inhibition potentiates responses to anti-CTLA4 in vivo
We next assessed whether HSP90 inhibition could enhance responses to T cell directed
immunotherapy in vivo. MC38/gp100 tumour bearing mice were treated with solvent/antibody
control (vehicle), ganetespib, anti-CTLA4 or the combination of ganetespib and anti-CTLA4.
Treatment with ganetespib was started at the same time as anti-CTLA4 (Figure 10A). The
combination of ganetespib and anti-CTLA4 conferred a better anti-tumour response, compared
to either treatment alone (Figure 10B) and a better survival compared to either treatment alone
(Figure 10C) with the median survival in the vehicle = 21days, ganetespib = 24 days, anti-CTLA4
= 22.5 days and the combination of ganetespib and anti-CTLA4 = 28 days. Taken together, the
results of the in vivo studies indicate that HSP90 inhibition enhances responses to anti-CTLA4
therapy.

The combination of HSP90 inhibition and anti-CTLA4 treatment enhances the effector
function of CD8 T cells
To investigate whether HSP90 inhibition and anti-CTLA4 treatments modulate the immune
cell population infiltrating the tumour, C57BL/6 mice were treated with vehicle, ganetespib, antiCTLA4, or the combination of ganetespib and anti-CTLA4, starting day 7 after inoculation with
MC38/gp100 tumours (Figure 11A). In tumours harvested on day 18 after tumour inoculation, the
absolute number of CD8 T cells (Figure 10B) and Ki67 positive CD8 T cells (Supplemental Figure
6A) were highest in the combination treatment, but the difference between the anti-CTLA4 only
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and combination groups was not statistically significant, suggesting that ganetespib treatment
does not further increase trafficking or proliferation of CD8 T cells in the tumour. However, the
number of T regulatory cells (Tregs) was significantly decreased in the treatment groups
compared to the vehicle (Figure 11C); both anti-CTLA4 and HSP90 inhibitor treatments alone
have been shown to decrease the number of tumour-infiltrating Tregs (217, 218). This resulted in
an increased CD8 T cell to Treg ratio in the treatment groups, with the difference between the
combination group and the other groups being statistically significant (Figure 11D). Other cell
populations such as myeloid derived suppressor cells (MDSCs) and effector CD4 T cells
remained unchanged (Supplemental Figure 6B-C). To investigate whether the increase in CD8 T
cell to Treg ratio had an impact on CD8 T cell effector function, production of the cytotoxic
molecules granzyme A and granzyme B by CD8 T cells was assessed. The number of CD8 T
cells making granzymes A and B was significantly higher in the combination treatment group
compared to the other treatment groups (Figure 11E-F & Supplemental Figure 6D), suggesting
that the combination treatment enhanced the effector function of CD8 T cells infiltrating the
tumour. Furthermore, to interrogate whether the generation of antigen specific cells was affected
by treatment, splenocytes isolated from the treated mice were stimulated ex vivo with either
DMSO as a control, gp100 or p15E peptides (MHC I restricted peptides expressed by the
MC38/gp100 tumour), and IFN-gamma production was assessed by ELISPOT. Results indicated
a significant increase in IFN-gamma producing cells following stimulation with gp100 peptide in
the treatments groups with the increase being the most dramatic in the combination treatment
group (Figure 12), suggesting that the treatment of ganetespib and anti-CTLA4 enhances antigen
specific CD8 T cell generation. Stimulation with P15E peptide showed a similar trend although
the increase was not statistically significant in the anti-CTLA4 and combination groups. Taken
together, these results suggest that the combination of HSP90 inhibition and anti-CTLA4 therapy
enhances the generation of antigen specific CD8 T cells and the effector function of CD8 T cells.
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Discussion and future directions
In this study, HSP90 inhibitors were identified as promising combination partners with
immunotherapy. Many known oncogeneic drivers are client proteins of HSP90 which regulate
tumor intrinsic pathways, some of which may provide a route of interference with response to
immunotherapy (203, 214, 219, 220). However, HSP90 inhibitors as single agents, have shown
limited therapeutic activity in cancer patients but encouraging responses when combined with
other targeted therapies (207, 210). Studies from our group and others provide an indication for
combining HSP90 inhibition with immunotherapy. Preclinical studies from the Storkus group using
the first generation HSP90 inhibitor 17-DMAG provided initial evidence of HSP90 as a tumor
intrinsic molecule that could be targeted to enhance responses to immunotherapy in a vaccine
model (221, 222). We now provide evidence that HSP90 inhibition enhances T cell mediated
killing of melanoma cells and, for the first time, potentiates responses to immune checkpoint
blockade in vivo (Supplemental figure 5).
HSP90 is ubiquitously expressed and is vital in a number of important processes involved
in the integration of innate and adaptive immune responses. These include antigen processing
and presentation, activation and cross-priming of lymphocytes, and DC activation/maturation.
Therefore, combination therapy with inhibition of HSP90 does not initially appear a reasonable
approach for improving the T cell mediated antitumor functions observed with immune checkpoint
blockade. As part of the classical endogenous pathway of antigen processing and presentation,
peptides are delivered to the surface bound to MHC I molecules(219). Data from in vitro studies
suggest that HSP90 may be vital for the binding and delivery of chaperoned, antigenic peptides
with MHC I molecules to the cell surface. Moreover, via a nonclassical, MHC II– mediated
mechanism for presentation of intracellular tumor antigens HSP90 can also facilitate direct tumor
recognition by CD4 T cells . While, these studies provided valuable information on the role of
HSP90 in antigen processing and presentation, it should be noted that the model systems used
involved either a complete knockout of HSP90 or the use of extremely high concentrations of the

60

first generation inhibitors (up to 30uM). Studies from our group and other groups show that
inhibiting HSP90 transiently with lower concentrations of the HSP90 inhibitors have provided
evidence that HSP90 inhibition can enhance responses to immunotherapy. For instance, 17-AAG
has been shown to upregulate the expression of melanoma antigens on the surface thereby
enhancing T cell recognition. This observation was also validated and confirmed in an expanded
study evaluating the capacity of 12 different and structurally diverse HSP90 inhibitor compounds,
to increase the expression of tumor-specific differentiation antigens in a panel of glioma and
melanoma cell lines. In addition, HSP90 inhibition has also been shown to upregulate MHC I
expression, a synergistic effect that combines with the enhanced antigen expression to promote
increased T cell recognition of treated tumours. Moreover, studies from the Storkus’ group, using
cells expressing the well-established HSP90 client protein EphA2, provide compelling evidence
of HSP90 inhibition enhancing response to immunotherapy in a vaccine model(221, 222). In these
series of studies, 17-DMAG enhanced tumour recognition by EphA2 specific CD8 T cells via
enhanced proteasomal degradation of and subsequent MHC-dependent presentation of EphA2
derived antigens. In complementary in vivo studies, EphA2-expressing sarcoma tumours were
treated with 17-DMAG and an EphA2 vaccine. The stimulation of adoptively transferred T cells
by the EphA2 vaccine resulted in the generation CD8 T cells which potentiated the tumour
inhibitory effects of 17-DMAG. In addition, 17-DMAG treatment led to a reduction in suppressor
cell populations, including Tregs and MDSCs. This is consistent with our current study, where we
see an enhancement of T cell mediated killing of ganetespib treated tumour cells by T cells in
vitro. As well as, a potentiation of immune checkpoint blockade function in vivo, characterized by
delayed tumour progression, enhance CD8 T cell function and a decrease in Tregs. The decrease
in Tregs is probably due to the fact that Tregs are extremely dependent on the HSP90 homologue
GRP94 to maintain TGF-β production, as recently described in a study from Zhang and
colleagues(223). However, follow up studies will be need to confirm this phenomenon in this
setting. Taken together, the previously considered negative characteristic of HSP90 inhibitors
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could actually to assist in the generation of antitumour immunity and potentiate various forms of
immunotherapy.
Another setting in which HSP90 inhibitors have been reportedly used is in inflammatory
autoimmune models. A high titer of autoantibodies to HSP90 in the sera of systemic lupus
erythematosus (SLE) patients, as well as the elevated expression of HSP90 in kidneys and sera
of SLE patients, prompted the preclinical investigation of HSP90 inhibition in SLE. In a study by
Shimp and colleagues, the treatment of MRL/lpr mice (the most commonly used mouse model of
SLE) with the HSP90 inhibitor 17-DMAG led to a decrease in the number of follicular B cells
accompanied by a decrease in the levels of double negative T cells and the CD4/CD8 ratio. This
provided evidence that HSP90 may be important in regulating T cell differentiation and activation
and blocking these events through HSP90 inhibition may be a promising therapeutic strategy in
lupus (224-226). In another study, DCs were shown promote autoimmune responses in SLE.
GRP94 was shown to induce DC activation in SLE, as such blocking the maturation of these cells
via HSP90 inhibitor treatments was proposed as a potential therapeutic approach (227, 228).
These studies provide evidence that HSP90 in important in various aspects of the generation of
an immune response. Notably, the impairment of the generation and functions of different immune
cell compartments would come as a result of frequent and/or continuous dosing of the HSP90
inhibitor. For instance, administration of the HSP90 inhibitor on a schedule of twice a week for 14
weeks in a murine model of SLE or a schedule of once daily for 14 weeks in an epidermolysis
bullosa acquisita model (224, 229). However, in the oncology setting, studies have shown tumour
selectivity and retention of HSP90 inhibitors. These properties of HSP90 inhibitor compounds
have permitted intermittent dosing regimens that lead to effective and sustained inhibition of
chaperone inhibitory activity within the tumour compartment coupled with restricted systemic
immune system drug exposures. Therefore there has to be careful consideration for length of the
duration of HSP90 inhibitor treatments in clinical evaluation.
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We also demonstrate for the first time that HSP90 inhibition upregulates interferon
response genes in the tumor, notably IFIT1, IFIT2 and IFIT3, both in vitro and in vivo. There is
now increasing evidence that The IFIT genes, whose major roles have been previously described
in response to viral infections, also have a role in tumour biology. Particularly, IFIT2
overexpression in tumour cells promotes tumour cell death(230). In addition recent studies reveal
that a higher expression of interferon response genes, including the genes interrogated in this
study, have been associated with long term benefits to anti-CTLA4 immunotherapy across
multiple cancer types(231). In this study by Chiappinelli and colleagues, DNA methyltransferase
inhibitors (DNMTis) triggered cytosolic sensing of double-stranded RNA (dsRNA) resulting in the
increased expression of type I interferon response genes and apoptosis of ovarian cancer (OC)
cells. Basal levels of these interferon response genes positively correlated significantly with an
endogenous retrovirus (ERV) signature for multiple tumor types from samples in The Cancer
Genome Atlas. We now show specifically that IFIT2 and other family members IFIT1 and IFIT3,
when overexpressed in tumor cells, enhance T cell killing of tumor cells. Importantly, silencing of
these genes abrogated the enhanced T cell killing of melanoma cells following HSP90 inhibition.
This provides additional evidence that these genes play an essential role in inducing death of
tumor cells and their importance in potentiating response to T cell mediated immunotherapy. The
mechanism of interferon response genes upregulation following HSP90 inhibition in our
melanoma cell lines is still unknown. Evaluation of the presence of increased ERV expression
following HSP90 inhibition proved futile (data not shown). This was probably due to the fact that
our HSP90 inhibitor treatments were only 24hrs long, which is not enough time to reverse any
existent DNA hyper methylation, suggesting an alternate mechanism. It is known that HSP90
inhibition leads to the upregulation of the heat shock protein family member HSP70. In addition,
HSP70 has been shown to be upregulated and secreted in situations of cellular stress, such a
viral infection or heat shock. Secreted HSP70 acts as a PAMP, and can activate DCs via
TLR2/TLR4 inducing a type 1 interferon response as well as induction of antigen
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presentation(232). It is possible that the stress induced by HSP90 inhibition leads to the secretion
of HSP70 which can in turn induce and interferon response in our treated melanoma cell lines.
Examination of gene expression data shows an upregulation of HSP70 in ganetespib treated cell
lines (Supplemental figure 6E). In addition, mass spectrometry analysis of supernatants obtained
from ganetespib treated cells indicate and increase in HSP70 secretion compared to control
(Supplemental figure 6F). However, studies to confirm the secretion and stimulation of tumour
cells by HSP70 following HSP90 inhibitor will have to be performed.
In summary, this study provides evidence that HSP90 inhibition can potentiate T cell
mediated anti-tumor immune responses and supports exploration of the combination of
immunotherapy and HSP90 inhibitors in the clinic. Moreover, with the recent identification of
aberrations in the IFN pathway as a mechanism of immune resistance, this provides another
avenue of investigation of whether HSP90 inhibitors may play a role in reversing this resistance
(233-235).
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Figure 3: Several HSP90 clients involved in the hallmarks of cancer
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Open Conformation

Closed Conformation

Figure 4: HSP90 structural domains and conformations
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Figure 5: The HSP90 chaperone cycle
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Figure 6: Examples of first and second generation HSP90 inhibitors

68

69

70

71

72

73

74

Chapter 3
Deciphering the role of the transcription factor Runx2 in CD8
T cell function
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Abstract
T cells play an important role in cancer immunosurveillance and tumour destruction. By
transferring ex vivo expanded tumour-infiltrating T cells (TILs), around 50% of melanoma patients
can achieve an objective clinical response. While adoptive T-cell therapy (ACT) is very effective
in some patients, many patients fail to respond or first respond but then progress. This
underscores the need for overcoming the limiting factors in adoptive T cell therapy. One critical
limiting factor in ACT is the immunosuppressive tumour microenvironment, which impairs the
effector functions of transferred TILs at tumour sites. However, the fact that the underlying
suppressive pathways in tumour-reactive T cells have not entirely been identified and
characterized has seriously impeded our progress in developing new strategies to help more
melanoma patients to achieve favorable clinical outcomes.
Using a murine ACT model transferred CD8 T cells were recovered from the spleen and
tumour on day 6 and 13 following adoptive transfer. Gene expression profiling of T cells isolated
form the spleen compared those isolated at the tumour site revealed the upregulation of the
transcription factor Runx2 in the T cells from the tumour site. Therefore, we hypothesize that the
transcription factor Runx2 plays a critical role in regulating the effector functions of tumourreactive T cells. Runx2 overexpressing Pmel conferred a worse antitumour effect compared to
the control cells. Furthermore, the T cells in circulation and at the tumour site were decreased in
the mice that received Runx2 overexpressing Pmel compared to the control mice. Further
investigation revealed that Runx2 regulated processes in T cells such as cytokine production and
differentiation status, processes which are important in controlling tumour growth.
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The persistence of T cells in ACT
As mentioned in chapter 1, the persistence and effector function of adoptively transferred TILs is
crucial to improving ACT. Durable clinical responses strongly depend on the persistence of the
infused TIL. As such, one of the major challenges in ACT is to obtaining ample numbers of tumourspecific T cells with the aptitude to persist long term once infused into patients(120). Reports
from several groups indicate that two T cell subsets comprise and contribute the most to long
term persistence of TIL. These include the least effector-differentiated memory T cells know as
central memory T cells (Tcm) and T memory stem cells (Tscm)(236). Residing in lymphoid organs,
Tcm and Tscm possess robust expansion potential upon antigenic re-encounter as opposed to
more differentiated memory T cells. Compared to Tscm/Tcm effector, effector memory T cells
(Teff/Tem) respond to antigen with immediate effector function upon homing to tissues though
their capacity to regenerate is reduced(237). Furthermore, human Tem are divided into
CD45RA− or CD45RA+ cells. The CD45RA+ cells, dubbed Temra, are believed to be the most
differentiated memory cells, characterized by decreased proliferative capacity, robust cytotoxic
potential, and a higher predisposition to apoptosis(238). Tscm have the ability to differentiate into
Tcm and Tem. They show a greater self-renewing potential as demonstrated by a positive
correlation of the amount of infused Tscm with early expansion after transfer and absolute
numbers of long-term persisting cells(239-241). Still, with very low numbers of Tscm found in the
periphery, extensive expansion would be essential resulting in loss of memory potential. This
drawback of low natural frequencies can be circumvented by targeting the Wnt/β-catenin pathway
in naive cells(242, 243). Targeting this pathway results in the arrest of Teff differentiation and the
promotion of memory-like CD8 T cells with Tscm features. While targeting Wnt signaling seems
to be effective in promoting stemness and inhibiting differentiation, it may limit the proliferation
and function of CD8 Tcells; therefore, further studies are required to evaluate suitability for ACT
improvement. Additional methods employed to generate sufficient Tscm include cytokine
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conditioning (IL-7, IL-15, and IL-21), addition of co-stimulatory antibodies such as 4-1BB and
inhibition of Akt signaling during ex vivo expansion of TILs(244, 245).
Transcriptional regulation of T cell differentiation
Over the years, there has been identification of several transcription factors that regulate effector
and memory CD8 T cell development. Remarkably, several of these transcription factors function
in pairs and form counter-regulatory axes to concurrently produce effector T cells that provide
both short- and long-term protection thereby regulating effector and memory cell potential. The
two T-box transcription factors T-bet and eomesodermin (EOMES), have been shown to have key
roles in the development and function of effector and memory CD8 T cells. In early CD8 T cell
activation, T-bet and EOMES direct CTL differentiation by induction of IFN-γ, granzyme B,
perforin, CXCR3 and CXCR4(246-249). Initially induced by TCR signaling, T-bet expression is
subsequently amplified by IL12 mediated signaling and mammalian target of rapamycin (mTOR)
activity in effector CD8 T cells(250). EOMES expression seems to be induced consequently to
that of T-bet in a RUNX3-dependent manner. T-bet and EOMES both collaborate to sustain
memory CD8 T cell homeostasis via IL-2Rβ (CD122) expression, enabling IL-15-mediated
signaling and the homeostatic proliferation of memory cells.

The transcriptional repressor,

BLIMP1 (PDRM1) is expressed by effector CD8 T cells and is primarily induced by IL2, IL12 and
IL21. BLIMP1 expression declines as memory CD8 T cells mature ensuing pathogen clearance.
As such BLIMP1 is expressed at the lowest levels in Tcm cells. BLIMP1 is part of a transcriptional
program promotes terminal effector cells and enhances CTL functions. A well characterized
antagonist of BLIMP1 activity, is the transcription factor BCL6. The expression of BCL6 has been
shown to be inversely correlated with that of BLIMP1 in both effector and memory CD8 T cells.
CD8 T cells that Overexpression of BCL6 in CD8 T cells results in the generation of increased
numbers of Tcm cells(251). Another pair of transcription factors with important roles in effector
and memory Cd8 T cell generation are inhibitor of DNA binding 2 (ID2) and ID3. ID2 and ID3
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seem to perform their roles in effector CD8 T cells in a separate but temporal manner. While ID2
promotes the survival of effector CD8 T cells in the cell transition from naïve to effector, ID3
promotes their survival from effector to memory cell transition(248). The transcription factors
STAT3 and STAT4 are also important in effector and memory CD8 T cells generation. All-in-all
CD8 T cell effector and memory differentiation is a process highly influenced by a delicate balance
of the expression and/or repression of several transcription factors (Figure 13). Effector CD8 T
cells acquire a more terminally differentiated phenotype associated with decrease in proliferative
capacity and survival as the expression or activity of T-bet, BLIMP1, ID2 and STAT4 increases.
In contrast, EOMES, BCL-6, ID3, TCF1 and STAT3, prevent terminal differentiation and/or help
to maintain memory cell properties, such as long-term survival, proliferative potential,
developmental plasticity and the ability to self-renew.
Runt-related transcription factor 2
The Runt-related transcription factor (Runx) family consists of three members, Runx1, Runx2 and
Runx3, characterized by a conserved DNA binding Runt homology domain (RHD). The RHD
mediates formation of a heterodimer with the common subunit CBFβ, which itself does not interact
with DNA but increases the transcriptional activity of the Runx proteins(252). Runx1 and Runx3
are important in T cell development, particularly in commitment of double positive T cells to the
CD8 T cell lineage by activation of CD8 and epigenetic silencing of CD4 in double negative T cells
respectively, thereby favoring the development of CD8 T cells (253-255). Runx3 is also important
in the development of effector and memory cells as it induces T-bet expression. Runx2 on the
other hand is well known for its indispensable role in bone development, primarily as a regulator
of osteoblast differentiation. Early in bone development, activation of Runx2 commits pluripotent
mesenchymal stem cells to the osteoblast lineage and activates downstream genes which are
important in osteoblast differentiation. In addition, Runx2 controls mature osteoblast
differentiation through inducing an anti-proliferative state thereby retaining cells in the G1 phase
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of the cell cycle(256). In addition, Runx2 is also essential for chondrocyte maturation(257). As
such, heterozygous loss of function of Runx2 through mechanisms such as missense mutations,
deletions, point mutations and insertion results in a rare genetic condition in humans known as
cleindocranial dysplasia (CCD)

characterized by lack of intramembranous bone formation,

hypoplasia or aplasia of the clavicle(258, 259). Mice heterozygous for Runx2 display lack
clavicular development and mirror the symptoms seen their human counterparts (258). Although
Runx2 has been extensively studied in bone development, little is known about its role in the
hematopoietic system. Recent studies indicate the importance of Runx2 in the development and
migration of plasmacytoid dendritic cells from the bone marrow to the periphery in a CCR5
dependent manner(260). Runx2 has been shown to be expressed in developing and mature T
cells, however, its role in the normal CD8 T cells has not yet been elucidated (261). In this chapter,
I evaluated the transcription factor Runx2 for its ability to regulate effector/memory CD8 T cells
differentiation.
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Results
Runx2 is upregulated in Pmel T cells at the tumour site
To mimic the clinical setting of adoptive T cell therapy and characterize the phenotype of tumourreactive T cells at the tumour, we used a murine ACT model in which B16, a gp100-expressing
tumour cell line was implanted in mice and treated with transgenic Pmel T cells which recognize
gp100 in the context of H-2Db (262, 263) (Figure 14A&B). On day 6 and 13 following T cell
transfer, transferred Pmel T cells were recovered from the spleen and tumour. To interrogate
novel pathways which may inhibit the functions of tumour-reactive T cells at the tumour site,
microarray and genome-wide gene expression analyses, were used to characterize the
differential expression profiles among Pmel T cells from different groups. Results demonstrated
that the profile of Pmel T cells isolated from the spleen of the tumour bearing mice differed
significantly from the profile of T cells isolated from the tumour, but was similar to the profile of T
cells isolated from the spleen of the tumour free mice (Figure 14C). Gene Set Enrichment
Analysis(GSEA)(264) demonstrated that the phenotype of tumour-reactive T cells is positively
correlated to the profile of exhausted T cell defined in previous study(265)(Figure 14D), indicating
the presence of suppressive pathways in tumour-reactive T cells at tumour sites. To select
candidate pathways for further study, we applied the guidelines listed in Figure 14E and found
that 720 genes were differentially expressed by T cells recovered from the tumour site, when
compared with those recovered from the spleen. One of the gene sets found to be differentially
expressed by ingenuity pathway analysis were genes involved in osteoblast differentiation (Figure
14F) including the transcription factors (TFs) Tcf7 and Runx2 (a gene whose role has not yet been
described in T cells). This suggested that Runx2 may play a role in regulating T cell function at
the tumour site.
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Runx2 expression impairs Pmel T cell antitumour response
The transcription factor Runx2 is well known for its role in osteoblast differentiation, however the
role of Runx2 has not been previously described in T cells. Given that transcription factors,
including Runx1 and Runx3, have been shown to play a critical role in the differentiation and
effector function of CD8 T cells, we hypothesized that Runx2 may regulate several processes in
T cells including effector function, survival, proliferation and as a result the antitumour effect of
CD8 T cells(266, 267). To investigate the role of Runx2 in the antitumour effect of CD8 T cells,
Runx2 was overexpressed using a retroviral vector system. We were unable to silence Runx2
using small hair pin RNAs (shRNAs) and so we used Runx2 heterozygous and homozygous
knockout cells generated from fetal liver transplants as described in Supplemental figure 7. Runx2
overexpression and deficiency was confirmed by qrtPCR and flow cytometry (Supplemental figure
8A&B). Runx2 overexpressing and deficient cells were adoptively transferred into B16 tumour
bearing mice and their antitumour activity was assessed by monitoring the tumour size. Mice that
received the Runx2 overexpressing Pmel had larger tumours compared to the control cells and
mice that received the Runx2 deficient Pmel had smaller tumours compared to the mice that
received WT Pmel (Figure 15A). Furthermore, there was no difference in the number of circulating
Pmel or number of Infiltrating Pmel in the mice that received Runx2 deficient Pmel compared to
wild type cells (data not shown). But, the T cells in circulation and at the tumour site were
decreased in the mice that received Runx2 overexpressing Pmel compared to the control mice,
suggesting that Runx2 negatively regulates the ability of CD8 T cells to control tumour growth
(Figure 145&C).

The transcription factor Runx2 regulates effector differentiation of P mel T cells
The differentiation status of T cells (effector vs memory) plays an important role in their antitumour
effect(268, 269). To investigate whether Runx2 expression affect the differentiation status of CD8
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T cells, control, Runx2 over, WT and Runx2 deficient Pmel T cells were cultured in IL2
supplemented medium for 24hrs without any stimulation (Supplemental Figure 9). Gene
expression analysis of the cultured cells revealed differential expression of genes pathways
involved in T cell effector vs memory differentiation. Amongst these genes were the following
classes of genes(270) : Effector/differentiation – Eomes, granzymes, perforin, Trafficking –
CXCR3, CXCL10 and Differentiation – CD62L (SELL). In addition genes such as Spp1 and
Tgfbr22 known to be regulated by Runx2 were also differentially expressed (Figure 16A). The
expression of multiple markers was confirmed by flow cytometry with makers such as CD62L,
Tcf7, Cxcr3 expression being decreased in the Runx2 overexpressing cells and increased in
Runx2 deficient cells. While, Lag3 and Blimp1 (Prdm1) expression were increased in Runx2
overexpressing cells and decreased in Runx2 deficient cells, consistent with reported markers
that differentiate effector cells from memory cells (Figure 16B&C). These data is suggest that
Runx2 expression promotes effector (possibly terminal effector) cell differentiation. Taken
together, Runx2 overexpression promotes more of a terminal effector phenotype while Runx2
deficiency promotes more of a memory phenotype which is beneficial for antitumour immunity.

Runx2 expression promotes effector functions reminiscent of terminal effector CD8 T cells
As mentioned above, Runx2 overexpression promotes more of an effector phenotype. As such
effector functions such as cytokine production and cytotoxic ability should be affected by Runx2
perturbation. Terminal effector cells are characterized by a decrease in their ability to produce
effector cytokines, decreased proliferation, increased apoptosis and increased cytotoxicity. To
test whether Runx2 perturbation affected cytokine production, control, Runx2 overexpressing,
WT and Runx2 deficient Pmel cells were stimulated in the presence of gp100 pulsed DCs, B16
and mc38gp100 tumours in vitro for 24hrs. Cytokine secretion was assessed via Luminex and
flow cytometry. Overexpression of Runx2 lead to a decrease in the secretion of the effector
cytokines IL2, TNF-α, GM-CSF and IFN-γ while a deficiency of Runx2 had the opposite effect.
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Conversely, Runx2 overexpression lead to an increase and/or sustained production of the
suppressive cytokines IL10 and Spp1 while a Runx2 deficiency had the opposite effect,
suggesting that Runx2 expression suppressed effector cytokine production (Figure 17A and
Supplemental figure 10A&B). To evaluate whether, the decrease in cytokine production was as a
result of decreased cell survival, control, Runx2, WT and Runx2 deficient cells were cultured for
24hrs and stained for annexin V. Although Runx2 deficiency had no effect on the survival of the
Pmel T cells, Runx2 overexpression lead to increased annexin V expression, suggesting that
Runx2 expression could promote apoptosis (Figure 17B). The proliferation of these cells was also
evaluated via Brdu incorporation and a similar result was obtained. Runx2 deficiency did not affect
Pmel proliferation, however, Runx2 overexpression lead to a decrease in Pmel proliferation
(Figure 17C). Furthermore, because many of the granzyme genes were differentially expressed
in the gene expression analysis, the cytotoxic ability T cells was evaluated via T cell mediated
lysis of tumour cells. Runx2 overexpressing pmel induced higher levels of caspase 3 in tumour
cells. Meanwhile, Runx2 deficient Pmel mediated decreased lysis of tumour cells (Figure 17D).
Taken together, the effector phenotype displayed by Runx2 overexpressing Pmel compared to
Runx2 deficient Pmel suggest that Runx2 promotes terminal effector differentiation of CD8 T cells
while Runx2 deficiency promotes a memory phenotype.
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Discussion and future directions
In this study, we identified the transcription factor Runx2 as a gene upregulated in CD8 T cells at
the tumour site compared to the spleen. Runx2, whose role has been well established in
osteoblast biology, has not yet been elucidated in T cells. Studies over the years have shown that
subsets of effector and memory CD8 T cells can be differentiated by the cell surface and
intracellular markers they express, their trafficking patterns, as well as their ability to perform
effector functions. Terminally differentiated CD8 T cells or terminal effector CD8 T cells (TEF)
express low levels of the cell surface markers CD62L and Cxcr3 amongst others, while expressing
high levels of inhibitory receptors such as Lag3 and Klrg1. They also display low levels of the
transcription factor Tcf7 and high levels of the transcription factor Blimp1. They have decreased
effector cytokine secretion, increased inhibitory cytokine secretion and increased cytotoxicity.
Central memory T cells (Tcm) on the other hand display an opposite phenotype from TEF.
Perturbation of Runx2 in CD8 T cells revealed that Runx2 expression promotes the differentiation
of a TEF phenotype, characterized by decreased effector cytokine production, decrease
proliferation, decreased survival and increased cytotoxicity, as well as surface and intracellular
markers consistent with those expressed by TEF CD8 T cells (Table 1). Meanwhile, Runx2
deficient T cells display more of a Tcm phenotype characterized by increased effector cytokine
secretion and decrease cytotoxic, as well as expression of surface and intracellular markers
consistent with those expressed by Tcm CD8 T cells.
Although Runx2 overexpressing Pmel T cells kill better, their antitumour activity was
impaired in our in vivo ACT studies. This seems counter intuitive, as cells with better cytotoxicity
should control tumours better. This could be explained by the fact that Runx2 overexpressing T
cells have decreased levels of the chemokine receptor Cxcr3, important for trafficking into
tumours. The chemokines Cxcl9 and Cxcl10 are the ligands for Cxcr3 and are usually expressed
in the tumour microenvironment in an ongoing antitumour immune response. Cxcl9 and Cxcl10
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are produced by myeloid cells in the tumour microenvironment as well as tumour cells
themselves. In addition, once T cells traffick into the tumour and interact with tumour cells, they
release IFN-γ which further upregulate these chemokines and induce a feedback loop chemokine
and cytokine expression bringing in more T cells. As observed in our in vitro studies, IFN-γ
secretion was also decreased in the Runx2 overexpressing cells. The decreased expression of
Cxcr3, coupled with decreased effector cytokine production could contribute greatly to the
decreased T cell infiltration into the tumour and hence impaired antitumour effect. The Runx2
deficient T cells on the other hand express higher levels of Cxcr3 and produce higher levels of
effector cytokines compared to the WT cells. Although they have decreased ability to kill, this may
be compensated for by the increased effector cytokine secretion, which can also have direct
inhibitory effects on the tumours cells as well as recruiting other immune cells. In contrast, Runx2
overexpression leads to the production of inhibitory cytokines such as IL10 and Spp1 (a Runx2
regulated cytokine). IL10 has been reported to be part of a fully/terminally differentiated
characteristic of CD8 T cells. In order words, TEF CD8 T cells produce IL10 as a regulatory
mechanism to suppress CD8 T cell immune response in an autocrine manner. In addition IL10
has also been shown to be produced by highly dysfunctional CD8 T cells. Spp1 on the other hand
has been shown to promote the differentiation of terminal effector CD8 T cells, although the
source of Spp1 in this study was from DCs. Here we show that CD8 T cells themselves produce
copious amounts of Spp1 following Runx2 overexpression. Runx2 deficient cells on the other
hand express very low levels of IL10 and Spp1. It is possible that these cytokines also contribute
to the potentiation of the TEF phenotype displayed by Runx2 overexpressing CD8 T cells. A
noteworthy point is the fact that Tcm regain their ability to lyse tumour cells rapidly once they reencounter antigen. The observation that Runx2 deficient T cells had decreased cytotoxicity
suggests that Runx2 may directly regulate T cell cytotoxicity and is required in moderate amounts
once Tcm re-encounter antigen.
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Under various stimulatory conditions, Runx2 upregulation was observed, suggesting that
Runx2 expression may be normally induced down stream of TCR signaling (Supplemental Figure
11). However, drawing parallels from osteoblast biology, some of the factors know to induce and
potentiate Runx2 expression during osteoblast differentiation or promote osteoblast differentiation
are suppressive to CD8 T cells. Factors such as Spp1, Tgf-β and IL10 are examples of such
factors. The tumour microenvironment is known to be immunosuppressive with tumour cells, as
well as other suppressive immune cells making these factors. It is possible that induction of Runx2
downstream of TCR signaling may be a naturally occurring phenomenon and necessary for the
acquisition of cytotoxic functions. However, the expression of inhibitory factors such as Tgf-β,
may further potentiate Runx2 expression promoting the differentiation of CD8 T cells to TEF cells.
Notably, Runx2 upregulation can also lead to the secretion of these suppressive factors by CD8
T cells themselves, potentiating this suppressive environment. Overall these correlations between
our in vitro and in vivo studies provide some hypotheses as to why the antitumour effect of the
Runx2 overexpressing Pmel cells was impaired. However, these observations will have to be
confirmed by in vivo studies evaluating the survival, trafficking and cytokine secretion. In addition,
in vivo studies will be needed to confirm the potentiation of the suppressive effects by factors such
as Tgf-β. Finally, combination studies of ACT with other costimulatory antibodies, in the context
of Runx2 overexpression may be necessary to find situations where the cytotoxic promoting ability
Runx2 can be harnessed while limiting its suppressive effects.
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Figure 13: Transcription factors expressed at various stages of T cell differentiation
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Chapter 4
Materials and Methods
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Study approval.
6-12 week old C57BL/6 mice were purchased from the Charles River Frederick research model
facility (Bethesda, MD). Mice were handled in accordance with protocols approved by the
Institutional Animal Care and Use Committee. The MC38/gp100 cell line was established as
previously described(130). B16 tumour cell line was obtained from ATCC. Human melanoma cell
lines 2338, 2400, 2549, 2559 and their autologous T cells were established from metastatic
melanoma patients enrolled in the adoptive cell therapy clinical trial at M.D. Anderson Cancer
Center according to previously described protocols (271). All cell lines were maintained in
complete cell culture medium as previously described (193).

Compound screen
A library of 850 bioactive compounds was purchased from Selleckchem. Patient derived human
melanoma cell lines were labelled with DDAO cell tracker dye. The labelled cells were then treated
with either 1 uM of each compound or DMSO alone for 24 hrs at 37oC in a 96 well format or
treated first with the compound or DMSO, washed off and co-cultured with autologous T cells at
a predetermined ratio for 3 hrs. The cells were then assayed for cleaved caspase 3 via flow
cytometry as previously described (272). A comboscore was calculated based on observed
changes in the percentage of T cell–induced apoptosis in tumour cells with or without compound
treatment. Compounds that enhance the sensitivity of tumour cells to T cell–mediated killing have
comboscores >1. Comboscore = ((Compound&Tcells – Compound)/(Tcells – DMSO))2.
Gene expression profiling (GEP) and analysis
The patient derived human melanoma cell lines 2338, 2400, 2549 and 2559 were treated in
duplicate with DMSO as a control or 125 nM of ganetespib for 24hrs at 37oC. Total RNA was
collected for GEP on Illumina human HT12v4.0 arrays as previously described (273). For each
cell line and gene probe, the log2 values of ganetespib duplicates were averaged and subtracted
96

by the log2 values of DMSO samples. The average of these subtracted values, across all 4 lines,
was then used to create a gene rank for analysis by gene set enrichment analysis (GSEA)
software, which uses a Kolgorimov-Smirnov statistic to determine the significance of distribution
of a set of genes within a larger, ranked data set(264). GEP data were also analyzed using
Ingenuity Pathway Analysis software, which scores canonical pathways by their consistent
change across all samples, with a positive z score indicating an increase in expression or
activation of the canonical pathway, and a negative z score indicating a decrease.
Quantitative real time PCR
Total RNA was extracted using RNAeasy plus mini kit (QIAGEN). 2ug of RNA was reverse
transcribed to cDNA using the High Capacity RNA-to-cDNA kit (Thermofisher). Quantitative real
time PCR was performed using the Taqman gene expression assay system according to
according to manufacturer’s instructions (Life Technologies). A list of the gene expression assays
used is provided in the Supplementary Table 1. Samples were normalized to GAPDH expression
level using 2-∆∆CT method.
Western blots
Samples were lysed in RIPA lysis buffer system (Santa Cruz) according to manufacturer’s
instructions. 50ug of protein in cell lysates were separated in 4-20% SDS polyacrylamide gels
and transferred to nitrocellulose membranes. Membranes were incubated with the following
primary antibodies against IFIT1 (Cell Signaling), IFIT2 (Abcam), IFIT3 (Abcam), cleaved PARP
(Cell signaling), BCL2 (Cell signaling) and β-actin (Cell Signaling). Anti-rabbit and anti-mouse IgG
antibodies tagged with horseradish peroxidase (Cell signaling) were used.
Generation of ORF-expressing tumour cells for in vitro T cell-killing assay
Viral particles containing ORF gene-of-interest were used to infect patient-derived melanoma
cells. To test the effect of overexpression of IFIT genes, freshly transduced cells were co-cultured
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with autologous T cells. ORF-positive cells were gated based on the expression of tagged GFP
via flow cytometry analysis.
Generation of shRNA-expressing tumour cells lines for in vitro T cell-killing assay
Viral particles containing either control shRNA or shRNAs of gene-of-interest were used to infect
patient derived melanoma cells. Stable cell lines expressing shRNAs targeting the IFIT genes
were generated by 2-week puromycin treatment after viral transduction. These established stable
cell lines were used for in vitro experiments. To test the effect of the knockdown of the IFIT genes
to the synergistic effect of ganetespib and T cell killing, freshly transduced cells were treated with
either ganestespib or DMSO for 24hrs and assayed as described above.
Treatments, immune cell tumour infiltration analysis and ELIPOT analyses
The HSP90 inhibitor ganetespib was provided by Synta Pharmaceuticals (Lexington, MA). Mice
were treated with a dose of 100mg/kg once weekly. Anti-CTLA-4 (9H10) was purchased from
BioXcell and was administered every 3 days at a dose of 100ug/mouse. Isotype antibody control
used was Polyclonal Armenian Hamster IgG. Treated mice were sacrificed on day 18 following
tumour inoculation and tumours and spleens were harvested. Tumours were dissected into
fragments by cutting, digested in tumour digestion buffer for 2 hours at 37ºC and filtered through
45µm nylon mesh. The tumour digestion buffer was made by dissolving 1mg/ml collagenase,
100µg/ml hyaluronidase and 20mg/ml Dnase (Sigma-Aldrich, St. Louis, MO) in RPMI medium.
Cell suspensions were stained for intracellular and extracellular protein markers of interest.
Stained samples were acquired on a BD LSRFORTESSA X-20 instrument and data analyzed
using Flowjo software. Staining antibodies were as follows: Anti-CD45 (30-F11, Tonbo
Biosciences), anti-CD8 (53-6.7, Tonbo Biosciences), anti-CD3 (145-2C11, Tonbo Bioscience),
anti-CD4 (RMA-5, Tonbo Biosciences), anti-Foxp3 (FJK-16s, eBioscience), anti-CD25 (PC61.5,
eBioscience), anti-Gr1 (RB6-8C5, Tonbo Biosciences), anti-Ly6C (HK1.4, Biolegend), anti-
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CD11b (M1/70, Tonbo Biosciences), anti CD11c (N418, Tonbo Biosciences), anti-F4/80 (BM8.1,
Tonbo Biosciences), anti-granzyme B (GB11, BD Bioscience), anti-granzyme A (GzA-3G8.5,
Affymetrix Inc.), anti-Ki67 (SolA15, Affymetrix Inc.) and anti-cleaved caspase 3 (550821, BD
Bioscience). Single cell suspensions of splenocytes were prepared and erythrocytes depleted
using ACK lysis buffer (Life technologies). The murine IFN-gamma single-color enzymatic
ELISPOT assay kit from Immunospot was used to assess IFN-gamma producing cells.
Splenocytes from 3 mice with similar tumour weights were combined within each treatment group
and 300,000 splenocytes were incubated with either DMSO, gp100 peptide (KVPRNQDWL) at
1ug/ml or p15E peptide (KSPWFTTL) at 1ug/ml for 24hrs at 37oC and assayed according to the
manufacturer’s instructions. Spots were counted and quantified using the CTL Immunospot
reader.
Fetal liver transplant
Fetal liver transplant was performed as previously described. Pmel mice were crossed with
Runx2+/- mice to obtain Runx2+/- Pmel. Runx2 homozygous mice (Runx2-/-) mice die at birth
due to an arrest in osteoblast maturation(259, 274, 275). A male and female Runx2+/- mouse
were mated for 24hrs. 14.5days in pregnancy, the female mouse was sacrificed. Fetus were
collected and fetal livers isolated. Adult female WT mice were sub lethally irradiated (1000 cGy)
and reconstituted via tail vein injections of fetal livers. Once the immune systems were
reconstituted, Runx2 deficiency was verified using Real Time PCR (RTPCR) and flow cytometry.
Primers for genotyping: Neo3F: AAG ATG GAT TGC ACG CAG GTT CTC, CbfaDB: CAC GGA
GCA CAG GAA GTT GGG. Runx2 antibody from cell signaling (D1L7F), Anti-rabbit IgG (H+L),
F(ab')2Fragment (Alexa Fluor® 488 Conjugate) #4412 was used as a secondary antibody.
In vivo Bioluminescence Imaging
Before imaging, mice were anesthetized with isoflurane and i.p. injected with 100 mL of 20 mg/mL
D-Luciferin (Xenogen Corp.). After 8 min, animals were imaged using an IVIS 200 system
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(Xenogen), according to the manufacturer's instructions. Living Image software (Xenogen) was
used to analyze data. Regions of interest were manually selected and quanti- fication was
reported as the average photon flux within regions of interest. The bioluminescence signal
detected was represented as photons/s/cm2 /sr.
Adoptive T cell transfer
Nine days before ACT, splenocytes from pmel-1 TCR/Thy1.1, Runx2+/- pmel-1 TCR/Thy1.1 and
Runx2-/- pmel-1 TCR/Thy1.1 transgenic mice were harvest and infected with a retroviral vector
encoding a modified firefly luciferase gene and green fluorescent protein as previously described.
After sorting based on green fluorescent protein expression, luciferase expression pmel-1 T cells
were used for ACT. Wild-type (WT) were subcutaneously implanted with either 500000 B16 cells
(day 0). On day 6, lymphopenia was induced by administering a nonmyeloablative dose (350 cGy)
of radiation. On day 7, 1e106 luciferase-expressing pmel-1 T cells were adoptively transferred into
tumor-bearing mice (n ¼ 3–5 per group), followed by intravenous injection of hgp100 peptidepulsed bone marrow–derived dendritic cells (DC) generated as previous described. Recombinant
human IL-2 was intraperitoneally administered for 3 d after T-cell transfer (1.2e106 IU once
immediately after T-cell transfer and 6e105 IU twice daily for the next 2 days). Tumor sizes were
monitored every 2 days.
Statistical analysis.
The data were represented as mean ± SEM. Comparisons of differences in continuous variables
between 2 groups were done using unpaired Student t tests. Comparisons of differences in
continuous variables within a group (DMSO vs peptide stimulation) were done using paired
Student t tests. Differences in tumour size and T-cell numbers among different treatments were
evaluated by ANOVA repeated-measures function. P values are based on 2-tailed tests, with P <
0.05 considered statistically significant. Graphs were generated using GraphPad Prism 6 and
Tableau. Statistical analyses were performed using GraphPad Prism 6.
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